# Walpole

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 20 | 27.9 | 71.6 | (43.7-110.5) |  | Male | 21 | 18.0 | 116.9 | (72.3-178.6) |
| Female | 11 | 10.3 | 106.3 | (53.0-190.3) |  | Female | 12 | 13.8 | 86.8 | (44.8-151.7) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 5.3 | nc | (nc-nc) |  | Male | 6 | 5.7 | 104.6 | (38.2-227.7) |
| Female | 7 | 4.4 | 157.6 | (63.1-324.7) |  | Female | 6 | 4.7 | 127.2 | (46.4-276.8) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 1.0 | nc | (nc-nc) |  | Male | 15 | 16.1 | 93.2 | (52.1-153.7) |
| Female | 136 | 112.9 | 120.5 | (101.1-142.5) |  | Female | 9 | 14.5 | 62.3 | (28.4-118.2) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 9 | 13.8 | 65.2 | (29.8-123.8) |
| Female | 1 | 3.7 | nc | (nc-nc) |  | Female | 6 | 6.0 | 99.3 | (36.3-216.2) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 36 | 30.8 | 116.8 | (81.8-161.7) |  |  |  |  |  |  |
| Female | 32 | 30.5 | 104.9 | (71.7-148.1) |  | Female | 13 | 9.7 | 133.9 | (71.2-229.0) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 4 | 7.3 | nc | (nc-nc) |  | Male | 11 | 10.1 | 108.6 | (54.1-194.3) |
| Female | 3 | 2.0 | nc | (nc-nc) |  | Female | 12 | 10.5 | 113.8 | (58.7-198.8) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 3 | 2.0 | nc | (nc-nc) |  | Male | 119 | 90.8 | 131.0 | (108.6-156.8) |
| Female | 1 | 1.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 17 | 15.9 | 106.6 | (62.1-170.7) |  | Male | 7 | 6.8 | 102.8 | (41.2-211.9) |
| Female | 7 | 9.0 | 78.2 | (31.3-161.0) |  | Female | 3 | 4.1 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 5 | 4.2 | 117.7 | (37.9-274.7) |  | Male | 5 | 3.5 | 143.3 | (46.2-334.4) |
| Female | 2 | 1.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 9 | 11.3 | 79.6 | (36.3-151.1) |  | Male | 4 | 7.2 | nc | (nc-nc) |
| Female | 10 | 8.3 | 121.2 | (58.0-222.8) |  | Female | 21 | 19.8 | 106.3 | (65.8-162.5) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 9 | 10.1 | 89.4 | (40.8-169.8) |  |  |  |  |  |  |
| Female | 3 | 3.4 | nc | (nc-nc) |  | Female | 25 | 25.1 | 99.5 | (64.3-146.8) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 41 | 49.7 | 82.5 | (59.2-111.9) |  | Male | 379 | 366.8 | 103.3 | (93.2-114.3) |
| Female | 45 | 53.7 | 83.8 | (61.1-112.2) |  | Female | 394 | 380.4 | 103.6 | (93.6-114.3) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

316

# Waltham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 62 | 54.1 | 114.6 | (87.9-147.0) |  | Male | 24 | 35.9 | 66.9 | (42.9-99.6) |
| Female | 20 | 20.5 | 97.6 | (59.6-150.7) |  | Female | 13 | 29.8 | 43.6 | (23.2-74.6) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 15 | 11.7 | 128.4 | (71.8-211.7) |  | Male | 11 | 11.1 | 99.1 | (49.4-177.3) |
| Female | 12 | 9.6 | 125.5 | (64.8-219.2) |  | Female | 4 | 9.3 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 2 | 1.9 | nc | (nc-nc) |  | Male | 23 | 32.2 | 71.4 | (45.2-107.1) |
| Female | 229 | 223.3 | 102.6 | (89.7-116.7) |  | Female | 34 | 29.1 | 117.0 | (81.0-163.5) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 17 | 26.0 | 65.3 | (38.0-104.6) |
| Female | 9 | 8.1 | 111.0 | (50.6-210.7) |  | Female | 8 | 12.1 | 66.0 | (28.4-130.1) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 63 | 58.9 | 106.9 | (82.1-136.8) |  |  |  |  |  |  |
| Female | 59 | 60.2 | 98.1 | (74.7-126.5) |  | Female | 19 | 19.7 | 96.4 | (58.0-150.6) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 7 | 13.9 | 50.3 | (20.2-103.7) |  | Male | 25 | 19.3 | 129.3 | (83.7-190.9) |
| Female | 5 | 4.0 | 125.1 | (40.3-292.1) |  | Female | 26 | 21.0 | 124.0 | (81.0-181.7) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 5 | 5.8 | 86.7 | (27.9-202.3) |  | Male | 140 | 167.9 | 83.4 | (70.1-98.4) |
| Female | 5 | 4.8 | 104.7 | (33.7-244.3) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 37 | 30.9 | 119.7 | (84.3-165.0) |  | Male | 18 | 13.2 | 136.5 | (80.9-215.8) |
| Female | 21 | 18.0 | 116.8 | (72.3-178.6) |  | Female | 10 | 8.2 | 122.2 | (58.5-224.7) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 6 | 8.1 | 74.1 | (27.0-161.2) |  | Male | 13 | 11.6 | 112.4 | (59.8-192.1) |
| Female | 3 | 2.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 19 | 23.1 | 82.3 | (49.5-128.5) |  | Male | 17 | 15.6 | 109.2 | (63.6-174.8) |
| Female | 15 | 17.4 | 86.2 | (48.2-142.1) |  | Female | 47 | 46.8 | 100.4 | (73.8-133.6) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 27 | 18.8 | 143.2 | (94.4-208.4) |  |  |  |  |  |  |
| Female | 4 | 6.7 | nc | (nc-nc) |  | Female | 41 | 49.7 | 82.5 | (59.2-111.9) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 103 | 96.5 | 106.8 | (87.1-129.5) |  | Male | 685 | 714.5 | 95.9 | (88.8-103.3) |
| Female | 100 | 106.2 | 94.2 | (76.6-114.5) |  | Female | 747 | 769.9 | 97.0 | (90.2-104.2) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

317

# Ware

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 7 | 10.8 | 65.1 | (26.1-134.1) |  | Male | 3 | 6.9 | nc | (nc-nc) |
| Female | 2 | 3.6 | nc | (nc-nc) |  | Female | 4 | 5.3 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 2.2 | nc | (nc-nc) |  | Male | 2 | 2.3 | nc | (nc-nc) |
| Female | 0 | 1.7 | nc | (nc-nc) |  | Female | 1 | 1.7 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 10 | 6.3 | 158.6 | (75.9-291.8) |
| Female | 34 | 44.8 | 75.9 | (52.5-106.1) |  | Female | 6 | 5.2 | 114.8 | (41.9-249.8) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 4 | 5.5 | nc | (nc-nc) |
| Female | 1 | 1.5 | nc | (nc-nc) |  | Female | 3 | 2.3 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 17 | 11.9 | 142.9 | (83.2-228.8) |  |  |  |  |  |  |
| Female | 14 | 10.8 | 130.1 | (71.1-218.4) |  | Female | 5 | 3.8 | 132.1 | (42.6-308.3) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 2.9 | nc | (nc-nc) |  | Male | 8 | 3.9 | 203.0 | (87.4-400.1) |
| Female | 1 | 0.7 | nc | (nc-nc) |  | Female | 6 | 3.7 | 161.1 | (58.8-350.6) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.8 | nc | (nc-nc) |  | Male | 26 | 37.5 | 69.4 | (45.3-101.7) |
| Female | 0 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 5 | 6.3 | 78.8 | (25.4-183.8) |  | Male | 2 | 2.6 | nc | (nc-nc) |
| Female | 8 | 3.5 | 231.4 | (99.6-455.9) |  | Female | 1 | 1.4 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 1.7 | nc | (nc-nc) |  | Male | 2 | 1.5 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 2 | 4.4 | nc | (nc-nc) |  | Male | 2 | 2.8 | nc | (nc-nc) |
| Female | 3 | 3.0 | nc | (nc-nc) |  | Female | 4 | 8.3 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 5 | 4.0 | 125.9 | (40.6-293.8) |  |  |  |  |  |  |
| Female | 2 | 1.2 | nc | (nc-nc) |  | Female | 9 | 10.1 | 89.2 | (40.7-169.3) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 20 | 19.4 | 103.3 | (63.1-159.5) |  | Male | 133 | 145.3 | 91.6 | (76.7-108.5) |
| Female | 20 | 20.0 | 99.8 | (60.9-154.1) |  | Female | 138 | 144.8 | 95.3 | (80.1-112.6) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

318

# Wareham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 36 | 29.0 | 124.3 | (87.0-172.1) |  | Male | 14 | 17.9 | 78.3 | (42.7-131.3) |
| Female | 16 | 10.1 | 158.3 | (90.4-257.1) |  | Female | 14 | 13.6 | 102.7 | (56.1-172.3) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 10 | 5.1 | 196.3 | (94.0-361.0) |  | Male | 11 | 5.8 | 188.4 | (93.9-337.2) |
| Female | 2 | 4.3 | nc | (nc-nc) |  | Female | 4 | 4.6 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 1.0 | nc | (nc-nc) |  | Male | 20 | 15.9 | 125.5 | (76.6-193.8) |
| Female | 93 | 113.3 | 82.1 | (66.2-100.5) |  | Female | 9 | 14.1 | 64.0 | (29.2-121.4) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 16 | 12.9 | 124.0 | (70.8-201.4) |
| Female | 2 | 3.6 | nc | (nc-nc) |  | Female | 6 | 6.0 | 100.6 | (36.7-218.9) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 32 | 30.4 | 105.4 | (72.1-148.7) |  |  |  |  |  |  |
| Female | 41 | 29.3 | 140.2 | (100.6-190.1) |  | Female | 7 | 9.7 | 72.1 | (28.9-148.6) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 7 | 7.2 | 96.6 | (38.7-199.0) |  | Male | 12 | 10.2 | 118.1 | (61.0-206.4) |
| Female | 2 | 2.0 | nc | (nc-nc) |  | Female | 17 | 10.2 | 167.2 | (97.3-267.7) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 1.9 | nc | (nc-nc) |  | Male | 90 | 85.4 | 105.3 | (84.7-129.5) |
| Female | 3 | 1.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 16 | 15.1 | 105.6 | (60.3-171.6) |  | Male | 5 | 6.9 | 72.5 | (23.4-169.2) |
| Female | 16 | 9.0 | 177.1 | (101.1-287.6) |  | Female | 3 | 3.9 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 5 | 4.3 | 117.2 | (37.8-273.5) |  | Male | 4 | 3.2 | nc | (nc-nc) |
| Female | 4 | 1.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 12 | 11.1 | 107.6 | (55.6-188.0) |  | Male | 6 | 6.5 | 92.4 | (33.7-201.1) |
| Female | 14 | 8.0 | 175.5 | (95.8-294.4) |  | Female | 17 | 19.6 | 86.6 | (50.4-138.7) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 14 | 9.7 | 144.3 | (78.8-242.2) |  |  |  |  |  |  |
| Female | 6 | 3.4 | 179.0 | (65.4-389.6) |  | Female | 21 | 25.7 | 81.8 | (50.6-125.1) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 74 | 51.7 | 143.1 | (112.4-179.7) |  | Male | 420 | 360.7 | 116.4 | (105.6-128.1) |
| Female | 81 | 54.1 | 149.7 | (118.8-186.0) |  | Female | 407 | 377.2 | 107.9 | (97.7-118.9) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

319

# Warren

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 6 | 5.4 | 110.2 | (40.3-239.9) |  | Male | 2 | 3.5 | nc | (nc-nc) |
| Female | 1 | 1.6 | nc | (nc-nc) |  | Female | 2 | 2.5 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 1.1 | nc | (nc-nc) |  | Male | 4 | 1.1 | nc | (nc-nc) |
| Female | 0 | 0.8 | nc | (nc-nc) |  | Female | 0 | 0.8 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 1 | 3.2 | nc | (nc-nc) |
| Female | 13 | 20.7 | 62.8 | (33.4-107.5) |  | Female | 1 | 2.4 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 2.8 | nc | (nc-nc) |
| Female | 1 | 0.7 | nc | (nc-nc) |  | Female | 0 | 1.0 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 7 | 6.1 | 114.1 | (45.7-235.0) |  |  |  |  |  |  |
| Female | 6 | 4.7 | 126.5 | (46.2-275.3) |  | Female | 0 | 1.7 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 3 | 1.4 | nc | (nc-nc) |  | Male | 7 | 2.0 | 353.9 | (141.8-729.2) |
| Female | 1 | 0.3 | nc | (nc-nc) |  | Female | 0 | 1.6 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 12 | 18.6 | 64.7 | (33.4-113.0) |
| Female | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 5 | 3.2 | 157.0 | (50.6-366.4) |  | Male | 1 | 1.3 | nc | (nc-nc) |
| Female | 1 | 1.6 | nc | (nc-nc) |  | Female | 0 | 0.6 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.8 | nc | (nc-nc) |  | Male | 4 | 0.8 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 3 | 2.2 | nc | (nc-nc) |  | Male | 0 | 1.5 | nc | (nc-nc) |
| Female | 1 | 1.4 | nc | (nc-nc) |  | Female | 3 | 4.0 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 1.9 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 5 | 4.5 | 110.0 | (35.5-256.7) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 10 | 9.7 | 103.2 | (49.4-189.8) |  | Male | 71 | 73.0 | 97.2 | (75.9-122.7) |
| Female | 9 | 9.0 | 99.9 | (45.6-189.7) |  | Female | 47 | 65.9 | 71.3 | (52.4-94.9) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

320

# Warwick

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 0 | 1.3 | nc | (nc-nc) |  | Male | 0 | 0.8 | nc | (nc-nc) |
| Female | 1 | 0.4 | nc | (nc-nc) |  | Female | 1 | 0.5 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 1 | 0.3 | nc | (nc-nc) |
| Female | 1 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 0 | 0.7 | nc | (nc-nc) |
| Female | 2 | 4.7 | nc | (nc-nc) |  | Female | 0 | 0.6 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 1 | 0.3 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 1 | 1.3 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 1.2 | nc | (nc-nc) |  | Female | 2 | 0.4 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 6 | 4.2 | 143.1 | (52.3-311.5) |
| Female | 0 | 0.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 0 | 0.7 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.7 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 1 | 1.2 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 3 | 2.4 | nc | (nc-nc) |  | Male | 12 | 16.4 | 73.2 | (37.8-127.8) |
| Female | 3 | 2.3 | nc | (nc-nc) |  | Female | 14 | 15.6 | 89.6 | (49.0-150.4) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

321

# Washington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 0 | 0.9 | nc | (nc-nc) |  | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 0.2 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 4 | 3.3 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 0 | 1.0 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 0.7 | nc | (nc-nc) |  | Female | 1 | 0.3 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 1 | 0.3 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 2 | 3.7 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.8 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 1 | 1.7 | nc | (nc-nc) |  | Male | 5 | 13.0 | 38.5 | (12.4-89.9) |
| Female | 1 | 1.6 | nc | (nc-nc) |  | Female | 10 | 10.4 | 95.8 | (45.9-176.3) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

322

# Watertown

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 30 | 29.9 | 100.4 | (67.7-143.3) |  | Male | 12 | 20.2 | 59.5 | (30.7-103.9) |
| Female | 10 | 12.9 | 77.4 | (37.1-142.3) |  | Female | 22 | 18.5 | 118.7 | (74.4-179.7) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 10 | 6.4 | 156.2 | (74.8-287.2) |  | Male | 4 | 6.4 | nc | (nc-nc) |
| Female | 8 | 5.7 | 141.2 | (60.8-278.3) |  | Female | 5 | 5.9 | 84.3 | (27.2-196.8) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 2 | 1.1 | nc | (nc-nc) |  | Male | 19 | 18.2 | 104.7 | (63.0-163.5) |
| Female | 140 | 143.5 | 97.5 | (82.1-115.1) |  | Female | 17 | 18.3 | 92.9 | (54.1-148.7) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 13 | 14.9 | 87.3 | (46.4-149.3) |
| Female | 10 | 5.2 | 191.8 | (91.8-352.7) |  | Female | 9 | 7.6 | 117.9 | (53.8-223.9) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 39 | 33.9 | 114.9 | (81.7-157.1) |  |  |  |  |  |  |
| Female | 35 | 37.3 | 93.9 | (65.4-130.6) |  | Female | 15 | 12.4 | 120.6 | (67.4-198.9) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 7 | 7.8 | 90.0 | (36.1-185.4) |  | Male | 11 | 10.8 | 101.5 | (50.6-181.7) |
| Female | 1 | 2.6 | nc | (nc-nc) |  | Female | 19 | 13.1 | 145.2 | (87.4-226.7) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 5 | 2.8 | 177.0 | (57.0-413.0) |  | Male | 68 | 93.0 | 73.2 | (56.8-92.7) |
| Female | 3 | 2.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 15 | 17.7 | 84.5 | (47.3-139.4) |  | Male | 9 | 7.5 | 120.7 | (55.1-229.2) |
| Female | 2 | 11.4 | nc | (nc-nc) |  | Female | 10 | 5.0 | 199.3 | (95.4-366.5) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 6 | 4.6 | 129.9 | (47.4-282.7) |  | Male | 6 | 5.8 | 102.8 | (37.5-223.8) |
| Female | 0 | 1.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 15 | 12.7 | 118.2 | (66.1-195.0) |  | Male | 8 | 8.9 | 89.9 | (38.7-177.1) |
| Female | 12 | 10.4 | 115.6 | (59.7-202.0) |  | Female | 29 | 28.9 | 100.3 | (67.2-144.0) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 8 | 10.7 | 74.7 | (32.1-147.1) |  |  |  |  |  |  |
| Female | 4 | 4.2 | nc | (nc-nc) |  | Female | 25 | 32.1 | 77.9 | (50.4-115.0) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 51 | 53.4 | 95.5 | (71.1-125.5) |  | Male | 369 | 399.0 | 92.5 | (83.3-102.4) |
| Female | 66 | 68.9 | 95.8 | (74.1-121.9) |  | Female | 480 | 486.7 | 98.6 | (90.0-107.9) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

323

# Wayland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 13 | 17.6 | 73.7 | (39.2-126.0) |  | Male | 18 | 10.8 | 166.3 | (98.5-262.9) |
| Female | 5 | 6.5 | 76.8 | (24.8-179.3) |  | Female | 13 | 8.3 | 157.4 | (83.7-269.2) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 3.1 | nc | (nc-nc) |  | Male | 4 | 3.6 | nc | (nc-nc) |
| Female | 2 | 2.7 | nc | (nc-nc) |  | Female | 3 | 2.9 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.6 | nc | (nc-nc) |  | Male | 7 | 9.7 | 72.0 | (28.9-148.4) |
| Female | 81 | 70.9 | 114.3 | (90.8-142.0) |  | Female | 13 | 9.0 | 145.0 | (77.2-248.1) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 2 | 8.0 | nc | (nc-nc) |
| Female | 2 | 2.1 | nc | (nc-nc) |  | Female | 4 | 3.7 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 13 | 18.6 | 69.8 | (37.1-119.4) |  |  |  |  |  |  |
| Female | 8 | 18.6 | 43.0 | (18.5-84.8) |  | Female | 5 | 6.0 | 82.8 | (26.7-193.2) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 4.4 | nc | (nc-nc) |  | Male | 4 | 6.2 | nc | (nc-nc) |
| Female | 0 | 1.3 | nc | (nc-nc) |  | Female | 8 | 6.5 | 122.8 | (52.9-241.9) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 1.0 | nc | (nc-nc) |  | Male | 62 | 53.2 | 116.5 | (89.3-149.3) |
| Female | 2 | 0.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 6 | 9.3 | 64.3 | (23.5-140.1) |  | Male | 2 | 4.2 | nc | (nc-nc) |
| Female | 4 | 5.7 | nc | (nc-nc) |  | Female | 0 | 2.5 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 2.6 | nc | (nc-nc) |  | Male | 3 | 1.6 | nc | (nc-nc) |
| Female | 0 | 0.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 7 | 6.8 | 102.3 | (41.0-210.9) |  | Male | 5 | 3.9 | 126.7 | (40.8-295.6) |
| Female | 2 | 5.0 | nc | (nc-nc) |  | Female | 11 | 11.2 | 98.1 | (48.9-175.6) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 5.9 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 2.1 | nc | (nc-nc) |  | Female | 13 | 16.0 | 81.1 | (43.2-138.7) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 18 | 31.1 | 57.9 | (34.3-91.5) |  | Male | 185 | 220.4 | 83.9 | (72.3-96.9) |
| Female | 19 | 34.8 | 54.6 | (32.8-85.2) |  | Female | 204 | 236.5 | 86.3 | (74.8-98.9) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

324

# Webster

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 27 | 20.4 | 132.1 | (87.0-192.2) |  | Male | 11 | 12.5 | 88.2 | (44.0-157.8) |
| Female | 6 | 7.6 | 78.9 | (28.8-171.8) |  | Female | 7 | 9.8 | 71.5 | (28.6-147.3) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 4 | 3.6 | nc | (nc-nc) |  | Male | 4 | 4.0 | nc | (nc-nc) |
| Female | 0 | 3.2 | nc | (nc-nc) |  | Female | 7 | 3.3 | 209.1 | (83.8-430.8) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 4 | 0.7 | nc | (nc-nc) |  | Male | 10 | 11.2 | 89.5 | (42.8-164.6) |
| Female | 83 | 76.8 | 108.1 | (86.1-134.1) |  | Female | 9 | 10.3 | 87.8 | (40.0-166.6) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 12 | 9.1 | 132.5 | (68.4-231.4) |
| Female | 4 | 2.6 | nc | (nc-nc) |  | Female | 5 | 4.2 | 118.2 | (38.1-275.9) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 21 | 21.6 | 97.0 | (60.0-148.3) |  |  |  |  |  |  |
| Female | 22 | 22.3 | 98.6 | (61.7-149.2) |  | Female | 12 | 6.7 | 179.7 | (92.7-313.9) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 9 | 5.0 | 178.3 | (81.3-338.4) |  | Male | 7 | 7.1 | 98.7 | (39.6-203.4) |
| Female | 2 | 1.4 | nc | (nc-nc) |  | Female | 6 | 7.8 | 76.8 | (28.0-167.1) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 3 | 1.4 | nc | (nc-nc) |  | Male | 56 | 60.2 | 93.0 | (70.2-120.7) |
| Female | 1 | 1.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 10 | 10.7 | 93.7 | (44.9-172.4) |  | Male | 3 | 4.8 | nc | (nc-nc) |
| Female | 11 | 6.3 | 175.8 | (87.7-314.6) |  | Female | 2 | 3.1 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 6 | 2.9 | 207.0 | (75.6-450.6) |  | Male | 3 | 2.5 | nc | (nc-nc) |
| Female | 2 | 0.9 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 11 | 7.9 | 139.2 | (69.4-249.1) |  | Male | 6 | 4.7 | 128.6 | (47.0-280.0) |
| Female | 5 | 6.1 | 82.1 | (26.4-191.5) |  | Female | 16 | 14.0 | 114.1 | (65.2-185.3) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 9 | 6.7 | 134.6 | (61.4-255.6) |  |  |  |  |  |  |
| Female | 5 | 2.4 | 211.3 | (68.1-493.0) |  | Female | 19 | 16.5 | 115.1 | (69.2-179.7) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 43 | 35.7 | 120.3 | (87.1-162.1) |  | Male | 287 | 253.5 | 113.2 | (100.5-127.1) |
| Female | 50 | 38.2 | 130.8 | (97.1-172.5) |  | Female | 302 | 267.7 | 112.8 | (100.5-126.3) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

325

# Wellesley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 19 | 29.5 | 64.5 | (38.8-100.7) |  | Male | 28 | 18.2 | 154.0 | (102.3-222.5) |
| Female | 6 | 9.9 | 60.6 | (22.1-131.8) |  | Female | 27 | 13.7 | 197.1 | (129.9-286.8) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 5.5 | nc | (nc-nc) |  | Male | 5 | 6.0 | 84.0 | (27.1-195.9) |
| Female | 5 | 4.9 | 102.2 | (32.9-238.4) |  | Female | 6 | 4.5 | 134.0 | (48.9-291.7) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 1.0 | nc | (nc-nc) |  | Male | 13 | 16.5 | 78.9 | (42.0-134.9) |
| Female | 142 | 110.5 | 128.5 | (108.3-151.5) |  | Female | 10 | 14.0 | 71.4 | (34.2-131.4) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 10 | 13.6 | 73.6 | (35.2-135.4) |
| Female | 2 | 3.6 | nc | (nc-nc) |  | Female | 5 | 5.9 | 84.9 | (27.4-198.2) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 22 | 31.6 | 69.7 | (43.7-105.5) |  |  |  |  |  |  |
| Female | 26 | 29.4 | 88.6 | (57.8-129.8) |  | Female | 11 | 9.6 | 115.0 | (57.3-205.7) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 7.5 | nc | (nc-nc) |  | Male | 11 | 10.4 | 105.9 | (52.8-189.5) |
| Female | 1 | 1.9 | nc | (nc-nc) |  | Female | 11 | 10.0 | 109.7 | (54.7-196.4) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 1.9 | nc | (nc-nc) |  | Male | 115 | 90.2 | 127.6 | (105.3-153.1) |
| Female | 2 | 2.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 14 | 16.0 | 87.7 | (47.9-147.1) |  | Male | 5 | 7.0 | 71.3 | (23.0-166.4) |
| Female | 5 | 8.8 | 57.0 | (18.4-133.0) |  | Female | 1 | 4.0 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 3 | 4.3 | nc | (nc-nc) |  | Male | 3 | 3.0 | nc | (nc-nc) |
| Female | 0 | 1.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 13 | 11.9 | 109.6 | (58.3-187.4) |  | Male | 8 | 6.9 | 116.6 | (50.2-229.7) |
| Female | 13 | 8.4 | 154.1 | (82.0-263.5) |  | Female | 20 | 21.1 | 94.6 | (57.8-146.1) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 4 | 9.9 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 3.3 | nc | (nc-nc) |  | Female | 21 | 24.0 | 87.6 | (54.2-133.9) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 17 | 51.7 | 32.9 | (19.1-52.6) |  | Male | 313 | 372.8 | 83.9 | (74.9-93.8) |
| Female | 34 | 51.8 | 65.6 | (45.4-91.7) |  | Female | 384 | 373.4 | 102.8 | (92.8-113.7) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

326

# Wellfleet

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 7 | 7.5 | 93.0 | (37.3-191.7) |  | Male | 4 | 4.2 | nc | (nc-nc) |
| Female | 2 | 2.9 | nc | (nc-nc) |  | Female | 2 | 2.9 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 1.0 | nc | (nc-nc) |  | Male | 0 | 1.4 | nc | (nc-nc) |
| Female | 2 | 0.9 | nc | (nc-nc) |  | Female | 0 | 1.2 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 6 | 3.7 | 161.8 | (59.1-352.2) |
| Female | 23 | 25.1 | 91.8 | (58.2-137.7) |  | Female | 1 | 3.5 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 3 | 2.9 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 0 | 1.4 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 6 | 7.0 | 86.1 | (31.4-187.3) |  |  |  |  |  |  |
| Female | 5 | 7.5 | 66.5 | (21.4-155.2) |  | Female | 2 | 2.2 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 1.8 | nc | (nc-nc) |  | Male | 0 | 2.5 | nc | (nc-nc) |
| Female | 1 | 0.6 | nc | (nc-nc) |  | Female | 5 | 2.9 | 171.5 | (55.3-400.2) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 19 | 22.1 | 85.9 | (51.7-134.1) |
| Female | 1 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 2 | 3.5 | nc | (nc-nc) |  | Male | 0 | 1.7 | nc | (nc-nc) |
| Female | 1 | 2.2 | nc | (nc-nc) |  | Female | 0 | 1.0 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 4 | 1.1 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 3 | 2.6 | nc | (nc-nc) |  | Male | 0 | 1.2 | nc | (nc-nc) |
| Female | 0 | 2.0 | nc | (nc-nc) |  | Female | 1 | 3.0 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 2.3 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 0.9 | nc | (nc-nc) |  | Female | 4 | 5.9 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 4 | 13.8 | nc | (nc-nc) |  | Male | 66 | 88.0 | 75.0 | (58.0-95.4) |
| Female | 12 | 15.1 | 79.3 | (40.9-138.6) |  | Female | 71 | 90.2 | 78.7 | (61.5-99.3) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

327

# Wendell

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 0 | 1.4 | nc | (nc-nc) |  | Male | 1 | 0.9 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 0 | 0.8 | nc | (nc-nc) |
| Female | 1 | 4.5 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 1 | 0.8 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 1 | 1.6 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.9 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 2 | 5.3 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 1 | 0.8 | nc | (nc-nc) |  | Male | 1 | 0.3 | nc | (nc-nc) |
| Female | 1 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 2 | 0.8 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 2 | 1.1 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 3 | 2.5 | nc | (nc-nc) |  | Male | 11 | 19.4 | 56.8 | (28.3-101.6) |
| Female | 2 | 1.9 | nc | (nc-nc) |  | Female | 9 | 14.0 | 64.2 | (29.3-122.0) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

328

# Wenham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 7 | 5.3 | 133.0 | (53.3-274.0) |  | Male | 5 | 3.1 | 158.8 | (51.2-370.6) |
| Female | 1 | 1.8 | nc | (nc-nc) |  | Female | 7 | 2.4 | 296.1 | (118.6-610.2) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.9 | nc | (nc-nc) |  | Male | 0 | 1.0 | nc | (nc-nc) |
| Female | 1 | 0.8 | nc | (nc-nc) |  | Female | 0 | 0.8 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 4 | 2.9 | nc | (nc-nc) |
| Female | 25 | 18.5 | 135.2 | (87.5-199.6) |  | Female | 2 | 2.5 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 3 | 2.2 | nc | (nc-nc) |
| Female | 1 | 0.6 | nc | (nc-nc) |  | Female | 1 | 1.0 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 1 | 5.4 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 9 | 5.3 | 170.5 | (77.8-323.7) |  | Female | 0 | 1.7 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 3 | 1.3 | nc | (nc-nc) |  | Male | 2 | 1.8 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 1 | 1.8 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 21 | 14.0 | 149.9 | (92.7-229.1) |
| Female | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 1 | 2.6 | nc | (nc-nc) |  | Male | 0 | 1.2 | nc | (nc-nc) |
| Female | 1 | 1.5 | nc | (nc-nc) |  | Female | 1 | 0.7 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.7 | nc | (nc-nc) |  | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 1 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 1 | 2.1 | nc | (nc-nc) |  | Male | 2 | 1.1 | nc | (nc-nc) |
| Female | 0 | 1.5 | nc | (nc-nc) |  | Female | 4 | 3.4 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 1.6 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 8 | 4.1 | 195.7 | (84.3-385.6) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 4 | 9.2 | nc | (nc-nc) |  | Male | 61 | 63.0 | 96.8 | (74.0-124.3) |
| Female | 11 | 9.2 | 119.5 | (59.6-213.9) |  | Female | 80 | 64.5 | 123.9 | (98.3-154.3) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

329

# West Boylston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 19 | 8.5 | 223.3 | (134.4-348.7) |  | Male | 6 | 5.7 | 106.2 | (38.8-231.1) |
| Female | 3 | 3.2 | nc | (nc-nc) |  | Female | 2 | 3.8 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 3 | 1.8 | nc | (nc-nc) |  | Male | 1 | 1.7 | nc | (nc-nc) |
| Female | 2 | 1.2 | nc | (nc-nc) |  | Female | 2 | 1.4 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.3 | nc | (nc-nc) |  | Male | 4 | 5.1 | nc | (nc-nc) |
| Female | 26 | 30.0 | 86.7 | (56.6-127.0) |  | Female | 3 | 4.2 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 4 | 4.2 | nc | (nc-nc) |
| Female | 1 | 0.9 | nc | (nc-nc) |  | Female | 1 | 1.7 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 5 | 9.2 | 54.1 | (17.4-126.2) |  |  |  |  |  |  |
| Female | 5 | 9.2 | 54.3 | (17.5-126.8) |  | Female | 6 | 2.7 | 224.6 | (82.0-489.0) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 2.2 | nc | (nc-nc) |  | Male | 2 | 3.1 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 6 | 3.3 | 180.6 | (65.9-393.0) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 1.0 | nc | (nc-nc) |  | Male | 28 | 27.6 | 101.4 | (67.4-146.6) |
| Female | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 8 | 4.9 | 163.0 | (70.2-321.1) |  | Male | 1 | 2.1 | nc | (nc-nc) |
| Female | 3 | 2.5 | nc | (nc-nc) |  | Female | 2 | 1.3 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 1.3 | nc | (nc-nc) |  | Male | 2 | 1.9 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 3 | 3.6 | nc | (nc-nc) |  | Male | 1 | 2.5 | nc | (nc-nc) |
| Female | 5 | 2.4 | 205.0 | (66.1-478.3) |  | Female | 11 | 4.8 | 231.5 | (115.4-414.3) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 3.0 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 1.0 | nc | (nc-nc) |  | Female | 4 | 6.8 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 25 | 15.1 | 165.2 | (106.9-243.9) |  | Male | 133 | 114.0 | 116.6 | (97.7-138.2) |
| Female | 16 | 15.8 | 101.0 | (57.7-164.0) |  | Female | 111 | 107.0 | 103.7 | (85.3-124.9) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

330

# West Bridgewater

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 9 | 8.5 | 106.4 | (48.6-202.0) |  | Male | 10 | 5.3 | 189.4 | (90.7-348.4) |
| Female | 3 | 2.7 | nc | (nc-nc) |  | Female | 4 | 3.7 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 5 | 1.6 | 319.9 | (103.1-746.5) |  | Male | 0 | 1.7 | nc | (nc-nc) |
| Female | 2 | 1.2 | nc | (nc-nc) |  | Female | 0 | 1.3 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 8 | 4.8 | 167.8 | (72.2-330.6) |
| Female | 38 | 30.8 | 123.5 | (87.4-169.5) |  | Female | 9 | 3.8 | 234.5 | (107.0-445.3) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 6 | 3.9 | 152.7 | (55.7-332.3) |
| Female | 1 | 1.0 | nc | (nc-nc) |  | Female | 2 | 1.6 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 7 | 9.1 | 77.2 | (30.9-159.1) |  |  |  |  |  |  |
| Female | 17 | 8.0 | 212.6 | (123.8-340.4) |  | Female | 1 | 2.6 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 5 | 2.2 | 229.9 | (74.1-536.5) |  | Male | 1 | 3.0 | nc | (nc-nc) |
| Female | 1 | 0.5 | nc | (nc-nc) |  | Female | 4 | 2.8 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.6 | nc | (nc-nc) |  | Male | 21 | 26.6 | 79.0 | (48.9-120.8) |
| Female | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 4 | 4.6 | nc | (nc-nc) |  | Male | 2 | 2.0 | nc | (nc-nc) |
| Female | 3 | 2.4 | nc | (nc-nc) |  | Female | 0 | 1.1 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 1.3 | nc | (nc-nc) |  | Male | 3 | 1.0 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 3.3 | nc | (nc-nc) |  | Male | 2 | 2.0 | nc | (nc-nc) |
| Female | 1 | 2.2 | nc | (nc-nc) |  | Female | 11 | 5.5 | 201.1 | (100.2-359.8) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 2.9 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.9 | nc | (nc-nc) |  | Female | 4 | 7.0 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 18 | 15.0 | 120.1 | (71.1-189.8) |  | Male | 111 | 108.3 | 102.5 | (84.3-123.4) |
| Female | 19 | 14.2 | 134.1 | (80.7-209.4) |  | Female | 129 | 102.5 | 125.9 | (105.1-149.5) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

331

# West Brookfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 3 | 5.3 | nc | (nc-nc) |  | Male | 5 | 3.2 | 154.7 | (49.8-361.0) |
| Female | 0 | 1.6 | nc | (nc-nc) |  | Female | 2 | 2.1 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 0.9 | nc | (nc-nc) |  | Male | 0 | 1.1 | nc | (nc-nc) |
| Female | 2 | 0.7 | nc | (nc-nc) |  | Female | 1 | 0.7 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 1 | 2.9 | nc | (nc-nc) |
| Female | 15 | 16.7 | 89.6 | (50.1-147.8) |  | Female | 3 | 2.2 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 1 | 2.4 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 3 | 0.9 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 3 | 5.5 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 2 | 4.6 | nc | (nc-nc) |  | Female | 4 | 1.5 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 1.3 | nc | (nc-nc) |  | Male | 0 | 1.8 | nc | (nc-nc) |
| Female | 1 | 0.3 | nc | (nc-nc) |  | Female | 0 | 1.7 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.3 | nc | (nc-nc) |  | Male | 13 | 16.0 | 81.1 | (43.1-138.6) |
| Female | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 3 | 2.8 | nc | (nc-nc) |  | Male | 2 | 1.3 | nc | (nc-nc) |
| Female | 1 | 1.4 | nc | (nc-nc) |  | Female | 0 | 0.6 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.8 | nc | (nc-nc) |  | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 1 | 2.0 | nc | (nc-nc) |  | Male | 0 | 1.2 | nc | (nc-nc) |
| Female | 0 | 1.3 | nc | (nc-nc) |  | Female | 1 | 2.9 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 4 | 1.8 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 6 | 3.9 | 153.7 | (56.1-334.4) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 7 | 9.2 | 75.9 | (30.4-156.3) |  | Male | 50 | 66.1 | 75.7 | (56.2-99.8) |
| Female | 14 | 8.4 | 166.1 | (90.7-278.6) |  | Female | 58 | 58.2 | 99.7 | (75.7-128.9) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

332

# West Newbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 7 | 4.4 | 159.8 | (64.0-329.3) |  | Male | 2 | 3.0 | nc | (nc-nc) |
| Female | 0 | 1.5 | nc | (nc-nc) |  | Female | 4 | 2.2 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 1.0 | nc | (nc-nc) |  | Male | 3 | 1.0 | nc | (nc-nc) |
| Female | 0 | 0.7 | nc | (nc-nc) |  | Female | 0 | 0.7 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 3 | 2.7 | nc | (nc-nc) |
| Female | 23 | 18.6 | 123.8 | (78.4-185.7) |  | Female | 0 | 2.2 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 2 | 2.4 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 1 | 0.9 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 4 | 5.1 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 4.4 | nc | (nc-nc) |  | Female | 1 | 1.6 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 1.2 | nc | (nc-nc) |  | Male | 2 | 1.7 | nc | (nc-nc) |
| Female | 1 | 0.3 | nc | (nc-nc) |  | Female | 1 | 1.5 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 21 | 16.0 | 131.5 | (81.4-201.0) |
| Female | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 6 | 2.7 | 218.4 | (79.7-475.3) |  | Male | 2 | 1.1 | nc | (nc-nc) |
| Female | 1 | 1.4 | nc | (nc-nc) |  | Female | 0 | 0.6 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.7 | nc | (nc-nc) |  | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 1 | 1.9 | nc | (nc-nc) |  | Male | 0 | 1.3 | nc | (nc-nc) |
| Female | 1 | 1.2 | nc | (nc-nc) |  | Female | 1 | 3.4 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 1.8 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 3 | 4.3 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 1 | 7.9 | nc | (nc-nc) |  | Male | 59 | 61.5 | 95.9 | (73.0-123.7) |
| Female | 4 | 7.9 | nc | (nc-nc) |  | Female | 47 | 59.3 | 79.3 | (58.2-105.4) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

333

# West Springfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 36 | 30.2 | 119.1 | (83.4-164.9) |  | Male | 14 | 19.2 | 73.0 | (39.9-122.5) |
| Female | 8 | 11.9 | 67.2 | (28.9-132.4) |  | Female | 11 | 15.9 | 69.2 | (34.5-123.8) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 7 | 6.0 | 116.8 | (46.8-240.7) |  | Male | 2 | 6.2 | nc | (nc-nc) |
| Female | 6 | 5.1 | 118.3 | (43.2-257.4) |  | Female | 4 | 5.3 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 1.0 | nc | (nc-nc) |  | Male | 20 | 17.2 | 116.2 | (70.9-179.4) |
| Female | 105 | 126.1 | 83.3 | (68.1-100.8) |  | Female | 13 | 16.3 | 79.6 | (42.3-136.1) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 16 | 14.2 | 112.6 | (64.3-182.9) |
| Female | 9 | 4.2 | 215.1 | (98.2-408.4) |  | Female | 6 | 6.8 | 88.5 | (32.3-192.6) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 43 | 32.0 | 134.4 | (97.3-181.1) |  |  |  |  |  |  |
| Female | 42 | 34.5 | 121.9 | (87.8-164.8) |  | Female | 7 | 10.9 | 64.1 | (25.7-132.0) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 12 | 7.8 | 153.3 | (79.1-267.8) |  | Male | 12 | 10.8 | 111.6 | (57.6-194.9) |
| Female | 1 | 2.3 | nc | (nc-nc) |  | Female | 8 | 12.1 | 66.3 | (28.6-130.7) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 2.4 | nc | (nc-nc) |  | Male | 79 | 95.4 | 82.8 | (65.6-103.2) |
| Female | 2 | 2.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 16 | 16.8 | 95.5 | (54.6-155.1) |  | Male | 5 | 7.3 | 69.0 | (22.2-160.9) |
| Female | 10 | 10.2 | 97.9 | (46.9-180.1) |  | Female | 5 | 4.7 | 107.1 | (34.5-250.0) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 4 | 4.6 | nc | (nc-nc) |  | Male | 6 | 4.3 | 139.1 | (50.8-302.7) |
| Female | 2 | 1.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 11 | 12.4 | 88.4 | (44.1-158.2) |  | Male | 12 | 7.5 | 160.1 | (82.6-279.7) |
| Female | 11 | 9.6 | 115.1 | (57.4-206.0) |  | Female | 25 | 23.1 | 108.2 | (70.0-159.7) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 12 | 10.6 | 113.2 | (58.4-197.7) |  |  |  |  |  |  |
| Female | 4 | 3.8 | nc | (nc-nc) |  | Female | 24 | 27.9 | 86.1 | (55.1-128.1) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 49 | 54.2 | 90.4 | (66.9-119.6) |  | Male | 386 | 391.5 | 98.6 | (89.0-108.9) |
| Female | 81 | 61.7 | 131.2 | (104.2-163.1) |  | Female | 423 | 431.5 | 98.0 | (88.9-107.8) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

334

# West Stockbridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 2 | 1.8 | nc | (nc-nc) |  | Male | 2 | 1.2 | nc | (nc-nc) |
| Female | 1 | 0.6 | nc | (nc-nc) |  | Female | 0 | 0.8 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 1 | 0.4 | nc | (nc-nc) |
| Female | 1 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 4 | 1.1 | nc | (nc-nc) |
| Female | 5 | 7.4 | 67.2 | (21.6-156.8) |  | Female | 2 | 0.9 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 0.9 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 1 | 0.4 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 0 | 2.0 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 1.7 | nc | (nc-nc) |  | Female | 0 | 0.6 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 0.5 | nc | (nc-nc) |  | Male | 1 | 0.7 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.6 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 9 | 6.7 | 134.0 | (61.1-254.3) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 0 | 1.1 | nc | (nc-nc) |  | Male | 1 | 0.5 | nc | (nc-nc) |
| Female | 1 | 0.6 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 0.7 | nc | (nc-nc) |  | Male | 1 | 0.5 | nc | (nc-nc) |
| Female | 2 | 0.5 | nc | (nc-nc) |  | Female | 0 | 1.2 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 0.7 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 2 | 1.8 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 7 | 3.5 | 201.6 | (80.8-415.4) |  | Male | 34 | 25.1 | 135.4 | (93.8-189.3) |
| Female | 0 | 3.6 | nc | (nc-nc) |  | Female | 17 | 24.3 | 70.0 | (40.8-112.1) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

335

# West Tisbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 7 | 2.0 | 349.8 | (140.1-720.8) |  | Male | 4 | 1.3 | nc | (nc-nc) |
| Female | 0 | 1.2 | nc | (nc-nc) |  | Female | 2 | 1.9 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 0.5 | nc | (nc-nc) |  | Male | 2 | 0.5 | nc | (nc-nc) |
| Female | 1 | 0.6 | nc | (nc-nc) |  | Female | 0 | 0.6 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 3 | 1.2 | nc | (nc-nc) |
| Female | 23 | 14.9 | 154.1 | (97.6-231.2) |  | Female | 4 | 1.8 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 1.1 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 1 | 0.8 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 3 | 2.3 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 4 | 3.8 | nc | (nc-nc) |  | Female | 2 | 1.3 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  | Male | 0 | 0.8 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 1 | 1.3 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 14 | 8.5 | 164.3 | (89.8-275.7) |
| Female | 1 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 4 | 1.3 | nc | (nc-nc) |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 0 | 1.1 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 0.4 | nc | (nc-nc) |  | Male | 1 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 1 | 0.9 | nc | (nc-nc) |  | Male | 2 | 0.6 | nc | (nc-nc) |
| Female | 1 | 1.0 | nc | (nc-nc) |  | Female | 0 | 2.7 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.8 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 4 | 3.6 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 1 | 3.9 | nc | (nc-nc) |  | Male | 47 | 29.6 | 158.7 | (116.6-211.0) |
| Female | 6 | 6.1 | 98.2 | (35.8-213.7) |  | Female | 55 | 48.7 | 112.9 | (85.0-146.9) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

336

# Westborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 13 | 17.8 | 73.1 | (38.9-124.9) |  | Male | 12 | 11.9 | 101.2 | (52.2-176.8) |
| Female | 8 | 6.9 | 115.7 | (49.8-228.0) |  | Female | 6 | 9.8 | 61.4 | (22.4-133.6) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 3 | 3.7 | nc | (nc-nc) |  | Male | 6 | 3.8 | 158.8 | (58.0-345.6) |
| Female | 6 | 3.2 | 190.4 | (69.5-414.5) |  | Female | 3 | 3.2 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.6 | nc | (nc-nc) |  | Male | 9 | 10.6 | 84.5 | (38.6-160.4) |
| Female | 79 | 78.1 | 101.2 | (80.1-126.1) |  | Female | 6 | 9.8 | 61.4 | (22.4-133.6) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 9 | 9.1 | 99.2 | (45.3-188.4) |
| Female | 1 | 2.6 | nc | (nc-nc) |  | Female | 3 | 4.2 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 19 | 20.4 | 93.1 | (56.0-145.4) |  |  |  |  |  |  |
| Female | 19 | 21.0 | 90.4 | (54.4-141.2) |  | Female | 5 | 6.7 | 74.3 | (24.0-173.5) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 3 | 4.7 | nc | (nc-nc) |  | Male | 6 | 6.5 | 92.8 | (33.9-202.0) |
| Female | 3 | 1.3 | nc | (nc-nc) |  | Female | 10 | 7.2 | 138.9 | (66.5-255.4) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 3 | 1.5 | nc | (nc-nc) |  | Male | 51 | 55.8 | 91.4 | (68.1-120.2) |
| Female | 2 | 1.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 4 | 10.5 | nc | (nc-nc) |  | Male | 5 | 4.4 | 113.3 | (36.5-264.3) |
| Female | 1 | 6.1 | nc | (nc-nc) |  | Female | 3 | 2.9 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 2.7 | nc | (nc-nc) |  | Male | 4 | 2.9 | nc | (nc-nc) |
| Female | 0 | 0.9 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 11 | 7.5 | 147.0 | (73.3-263.0) |  | Male | 7 | 5.1 | 137.0 | (54.9-282.3) |
| Female | 9 | 5.8 | 155.6 | (71.0-295.4) |  | Female | 13 | 14.6 | 88.8 | (47.2-151.9) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 5 | 6.5 | 77.4 | (24.9-180.6) |  |  |  |  |  |  |
| Female | 2 | 2.3 | nc | (nc-nc) |  | Female | 20 | 17.0 | 117.6 | (71.8-181.7) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 20 | 31.4 | 63.7 | (38.9-98.5) |  | Male | 213 | 236.5 | 90.1 | (78.4-103.0) |
| Female | 28 | 35.1 | 79.7 | (53.0-115.2) |  | Female | 245 | 261.4 | 93.7 | (82.3-106.2) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

337

# Westfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 43 | 43.1 | 99.8 | (72.2-134.4) |  | Male | 20 | 27.1 | 73.7 | (45.0-113.8) |
| Female | 14 | 14.5 | 96.4 | (52.7-161.8) |  | Female | 20 | 20.5 | 97.4 | (59.5-150.5) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 4 | 8.5 | nc | (nc-nc) |  | Male | 10 | 8.8 | 114.1 | (54.6-209.8) |
| Female | 6 | 6.8 | 88.4 | (32.3-192.5) |  | Female | 3 | 6.7 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 3 | 1.5 | nc | (nc-nc) |  | Male | 22 | 24.6 | 89.4 | (56.0-135.3) |
| Female | 198 | 164.0 | 120.7 | (104.5-138.8) |  | Female | 21 | 20.6 | 101.7 | (62.9-155.5) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 17 | 20.4 | 83.5 | (48.6-133.8) |
| Female | 8 | 5.4 | 148.8 | (64.1-293.3) |  | Female | 9 | 8.7 | 103.2 | (47.1-195.8) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 63 | 46.2 | 136.3 | (104.7-174.4) |  |  |  |  |  |  |
| Female | 51 | 42.4 | 120.2 | (89.5-158.1) |  | Female | 19 | 14.3 | 133.3 | (80.2-208.2) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 14 | 11.1 | 126.0 | (68.8-211.3) |  | Male | 13 | 15.3 | 84.8 | (45.1-145.1) |
| Female | 3 | 2.9 | nc | (nc-nc) |  | Female | 10 | 14.7 | 67.9 | (32.5-124.9) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 6 | 3.5 | 170.5 | (62.3-371.1) |  | Male | 122 | 136.5 | 89.3 | (74.2-106.7) |
| Female | 0 | 3.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 21 | 23.8 | 88.1 | (54.5-134.7) |  | Male | 11 | 10.3 | 106.6 | (53.1-190.7) |
| Female | 8 | 13.0 | 61.5 | (26.5-121.2) |  | Female | 8 | 5.8 | 138.2 | (59.5-272.3) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 4 | 6.4 | nc | (nc-nc) |  | Male | 7 | 6.1 | 114.5 | (45.9-236.0) |
| Female | 4 | 1.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 19 | 17.7 | 107.3 | (64.6-167.6) |  | Male | 6 | 10.7 | 56.0 | (20.5-122.0) |
| Female | 9 | 12.1 | 74.5 | (34.0-141.5) |  | Female | 22 | 30.9 | 71.2 | (44.6-107.7) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 13 | 15.0 | 86.8 | (46.2-148.5) |  |  |  |  |  |  |
| Female | 4 | 4.9 | nc | (nc-nc) |  | Female | 37 | 37.0 | 99.9 | (70.3-137.7) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 82 | 76.2 | 107.6 | (85.5-133.5) |  | Male | 549 | 557.9 | 98.4 | (90.3-107.0) |
| Female | 80 | 76.8 | 104.1 | (82.6-129.6) |  | Female | 566 | 551.0 | 102.7 | (94.4-111.5) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

338

# Westford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 15 | 20.1 | 74.5 | (41.7-122.9) |  | Male | 13 | 14.2 | 91.6 | (48.7-156.7) |
| Female | 4 | 6.4 | nc | (nc-nc) |  | Female | 12 | 10.7 | 112.2 | (57.9-196.0) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 7 | 4.6 | 151.5 | (60.7-312.3) |  | Male | 8 | 4.6 | 173.9 | (74.9-342.6) |
| Female | 5 | 3.6 | 140.3 | (45.2-327.4) |  | Female | 3 | 3.2 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.8 | nc | (nc-nc) |  | Male | 13 | 12.8 | 102.0 | (54.2-174.4) |
| Female | 105 | 90.9 | 115.5 | (94.4-139.8) |  | Female | 8 | 10.0 | 80.3 | (34.6-158.1) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 6 | 11.8 | 50.6 | (18.5-110.2) |
| Female | 2 | 3.2 | nc | (nc-nc) |  | Female | 3 | 4.4 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 25 | 24.0 | 104.1 | (67.3-153.6) |  |  |  |  |  |  |
| Female | 25 | 19.9 | 125.6 | (81.2-185.4) |  | Female | 6 | 7.5 | 79.5 | (29.0-173.0) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 4 | 5.9 | nc | (nc-nc) |  | Male | 9 | 7.8 | 116.0 | (52.9-220.3) |
| Female | 2 | 1.3 | nc | (nc-nc) |  | Female | 5 | 6.5 | 77.1 | (24.8-179.8) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 1.7 | nc | (nc-nc) |  | Male | 83 | 76.7 | 108.2 | (86.2-134.1) |
| Female | 3 | 1.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 10 | 13.5 | 73.8 | (35.3-135.7) |  | Male | 7 | 5.2 | 134.9 | (54.0-277.9) |
| Female | 3 | 6.7 | nc | (nc-nc) |  | Female | 1 | 2.7 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 4 | 3.5 | nc | (nc-nc) |  | Male | 3 | 2.9 | nc | (nc-nc) |
| Female | 0 | 1.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 10 | 8.8 | 113.0 | (54.1-207.9) |  | Male | 10 | 6.4 | 155.4 | (74.4-285.7) |
| Female | 9 | 5.7 | 157.2 | (71.7-298.5) |  | Female | 17 | 18.0 | 94.4 | (55.0-151.2) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 6 | 8.3 | 72.3 | (26.4-157.4) |  |  |  |  |  |  |
| Female | 0 | 2.3 | nc | (nc-nc) |  | Female | 34 | 20.4 | 166.8 | (115.5-233.1) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 32 | 38.1 | 84.1 | (57.5-118.7) |  | Male | 289 | 293.4 | 98.5 | (87.5-110.5) |
| Female | 25 | 36.0 | 69.4 | (44.9-102.4) |  | Female | 292 | 282.2 | 103.5 | (91.9-116.0) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

339

# Westhampton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 2 | 2.0 | nc | (nc-nc) |  | Male | 6 | 1.3 | 458.1 | (167.3-997.1) |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 0 | 0.9 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 0.4 | nc | (nc-nc) |  | Male | 1 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 0 | 1.2 | nc | (nc-nc) |
| Female | 10 | 7.8 | 128.8 | (61.7-236.9) |  | Female | 0 | 0.9 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 1 | 1.1 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 1 | 0.4 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 1 | 2.2 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 2 | 1.7 | nc | (nc-nc) |  | Female | 0 | 0.7 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 0.6 | nc | (nc-nc) |  | Male | 0 | 0.8 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.6 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 10 | 7.3 | 137.9 | (66.0-253.5) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 1 | 1.2 | nc | (nc-nc) |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 1 | 0.8 | nc | (nc-nc) |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 0 | 1.4 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.8 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 1 | 1.8 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 1 | 3.7 | nc | (nc-nc) |  | Male | 26 | 27.4 | 94.9 | (62.0-139.1) |
| Female | 0 | 3.2 | nc | (nc-nc) |  | Female | 14 | 24.4 | 57.4 | (31.3-96.2) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

340

# Westminster

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 6 | 7.9 | 76.0 | (27.7-165.4) |  | Male | 8 | 5.3 | 151.1 | (65.0-297.6) |
| Female | 3 | 2.3 | nc | (nc-nc) |  | Female | 6 | 3.7 | 160.9 | (58.8-350.3) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 1.6 | nc | (nc-nc) |  | Male | 1 | 1.7 | nc | (nc-nc) |
| Female | 1 | 1.2 | nc | (nc-nc) |  | Female | 1 | 1.1 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 6 | 4.8 | 126.2 | (46.1-274.8) |
| Female | 43 | 31.0 | 138.5 | (100.2-186.6) |  | Female | 2 | 3.5 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 5 | 4.3 | 116.8 | (37.6-272.5) |
| Female | 0 | 1.1 | nc | (nc-nc) |  | Female | 3 | 1.6 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 7 | 9.2 | 76.3 | (30.6-157.1) |  |  |  |  |  |  |
| Female | 7 | 7.0 | 99.3 | (39.8-204.7) |  | Female | 3 | 2.6 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 3 | 2.2 | nc | (nc-nc) |  | Male | 1 | 2.9 | nc | (nc-nc) |
| Female | 1 | 0.5 | nc | (nc-nc) |  | Female | 3 | 2.4 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  | Male | 23 | 27.2 | 84.5 | (53.6-126.8) |
| Female | 0 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 3 | 4.8 | nc | (nc-nc) |  | Male | 2 | 2.0 | nc | (nc-nc) |
| Female | 2 | 2.3 | nc | (nc-nc) |  | Female | 0 | 0.9 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 1.3 | nc | (nc-nc) |  | Male | 3 | 1.1 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 4 | 3.3 | nc | (nc-nc) |  | Male | 1 | 2.3 | nc | (nc-nc) |
| Female | 2 | 2.0 | nc | (nc-nc) |  | Female | 7 | 6.0 | 116.6 | (46.7-240.2) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 3.1 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.8 | nc | (nc-nc) |  | Female | 8 | 7.3 | 109.7 | (47.2-216.2) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 10 | 13.9 | 71.8 | (34.4-132.1) |  | Male | 98 | 108.2 | 90.6 | (73.5-110.4) |
| Female | 14 | 12.3 | 113.7 | (62.1-190.8) |  | Female | 107 | 97.8 | 109.4 | (89.7-132.2) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

341

# Weston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 18 | 15.3 | 117.8 | (69.8-186.2) |  | Male | 11 | 9.2 | 119.9 | (59.8-214.6) |
| Female | 1 | 5.0 | nc | (nc-nc) |  | Female | 9 | 6.5 | 138.8 | (63.3-263.4) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 4 | 2.7 | nc | (nc-nc) |  | Male | 3 | 3.0 | nc | (nc-nc) |
| Female | 1 | 2.2 | nc | (nc-nc) |  | Female | 4 | 2.3 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.5 | nc | (nc-nc) |  | Male | 10 | 8.2 | 122.0 | (58.4-224.3) |
| Female | 52 | 53.8 | 96.7 | (72.2-126.8) |  | Female | 3 | 6.9 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 7 | 6.7 | 104.5 | (41.9-215.3) |
| Female | 1 | 1.6 | nc | (nc-nc) |  | Female | 0 | 2.9 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 12 | 15.6 | 76.8 | (39.6-134.1) |  |  |  |  |  |  |
| Female | 10 | 14.6 | 68.6 | (32.9-126.2) |  | Female | 2 | 4.7 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 3.8 | nc | (nc-nc) |  | Male | 6 | 5.3 | 112.6 | (41.1-245.0) |
| Female | 0 | 1.0 | nc | (nc-nc) |  | Female | 11 | 5.1 | 214.5 | (106.9-383.8) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.8 | nc | (nc-nc) |  | Male | 47 | 46.4 | 101.3 | (74.5-134.8) |
| Female | 0 | 0.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 8 | 7.9 | 100.9 | (43.4-198.8) |  | Male | 2 | 3.6 | nc | (nc-nc) |
| Female | 1 | 4.3 | nc | (nc-nc) |  | Female | 0 | 2.0 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 2.2 | nc | (nc-nc) |  | Male | 2 | 1.2 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 6 | 5.9 | 101.0 | (36.9-219.8) |  | Male | 7 | 3.2 | 218.6 | (87.6-450.4) |
| Female | 6 | 4.1 | 147.2 | (53.7-320.3) |  | Female | 7 | 9.0 | 77.9 | (31.2-160.5) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 6 | 5.0 | 119.8 | (43.7-260.7) |  |  |  |  |  |  |
| Female | 0 | 1.7 | nc | (nc-nc) |  | Female | 9 | 12.1 | 74.2 | (33.8-140.8) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 15 | 27.3 | 54.9 | (30.7-90.5) |  | Male | 188 | 189.2 | 99.3 | (85.7-114.6) |
| Female | 17 | 26.3 | 64.8 | (37.7-103.7) |  | Female | 146 | 182.7 | 79.9 | (67.5-94.0) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

342

# Westport

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 25 | 23.8 | 104.9 | (67.8-154.8) |  | Male | 14 | 14.3 | 97.9 | (53.5-164.2) |
| Female | 7 | 7.1 | 98.1 | (39.3-202.0) |  | Female | 6 | 9.5 | 62.9 | (23.0-136.9) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 4.0 | nc | (nc-nc) |  | Male | 5 | 4.8 | 104.4 | (33.6-243.7) |
| Female | 2 | 3.0 | nc | (nc-nc) |  | Female | 4 | 3.3 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.8 | nc | (nc-nc) |  | Male | 16 | 12.8 | 124.8 | (71.3-202.6) |
| Female | 69 | 80.8 | 85.4 | (66.4-108.0) |  | Female | 15 | 10.0 | 149.9 | (83.8-247.3) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 8 | 10.3 | 77.6 | (33.4-153.0) |
| Female | 3 | 2.5 | nc | (nc-nc) |  | Female | 4 | 4.3 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 22 | 24.0 | 91.6 | (57.4-138.7) |  |  |  |  |  |  |
| Female | 19 | 20.4 | 93.0 | (56.0-145.2) |  | Female | 5 | 6.9 | 72.5 | (23.4-169.2) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 8 | 6.0 | 132.4 | (57.0-260.8) |  | Male | 13 | 8.3 | 157.0 | (83.5-268.5) |
| Female | 1 | 1.4 | nc | (nc-nc) |  | Female | 9 | 7.3 | 122.5 | (55.9-232.5) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 1.3 | nc | (nc-nc) |  | Male | 74 | 73.9 | 100.1 | (78.6-125.7) |
| Female | 0 | 1.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 8 | 12.4 | 64.7 | (27.9-127.5) |  | Male | 5 | 5.6 | 89.8 | (28.9-209.5) |
| Female | 6 | 6.3 | 94.6 | (34.6-206.0) |  | Female | 3 | 2.7 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 3 | 3.5 | nc | (nc-nc) |  | Male | 1 | 2.1 | nc | (nc-nc) |
| Female | 0 | 0.9 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 7 | 9.0 | 77.8 | (31.2-160.2) |  | Male | 6 | 5.0 | 119.0 | (43.5-259.0) |
| Female | 4 | 5.5 | nc | (nc-nc) |  | Female | 18 | 13.7 | 131.2 | (77.7-207.4) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 5 | 7.7 | 64.6 | (20.8-150.7) |  |  |  |  |  |  |
| Female | 1 | 2.4 | nc | (nc-nc) |  | Female | 11 | 18.8 | 58.4 | (29.1-104.5) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 36 | 42.6 | 84.4 | (59.1-116.9) |  | Male | 272 | 295.9 | 91.9 | (81.3-103.5) |
| Female | 41 | 38.4 | 106.7 | (76.6-144.8) |  | Female | 250 | 267.7 | 93.4 | (82.2-105.7) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

343

# Westwood

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 21 | 21.3 | 98.8 | (61.1-151.0) |  | Male | 26 | 12.5 | 208.1 | (135.9-305.0) |
| Female | 7 | 7.0 | 99.4 | (39.8-204.8) |  | Female | 20 | 8.7 | 230.3 | (140.6-355.7) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 3.5 | nc | (nc-nc) |  | Male | 7 | 4.1 | 171.9 | (68.9-354.2) |
| Female | 5 | 2.8 | 177.3 | (57.1-413.7) |  | Female | 4 | 3.1 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 2 | 0.7 | nc | (nc-nc) |  | Male | 9 | 11.3 | 79.5 | (36.3-150.9) |
| Female | 98 | 70.5 | 139.0 | (112.8-169.4) |  | Female | 6 | 9.5 | 63.5 | (23.2-138.2) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 7 | 8.9 | 78.9 | (31.6-162.6) |
| Female | 2 | 2.2 | nc | (nc-nc) |  | Female | 5 | 3.9 | 127.6 | (41.1-297.9) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 22 | 22.1 | 99.5 | (62.3-150.7) |  |  |  |  |  |  |
| Female | 22 | 20.8 | 105.6 | (66.1-159.8) |  | Female | 10 | 6.1 | 163.2 | (78.1-300.2) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 5.1 | nc | (nc-nc) |  | Male | 9 | 7.3 | 122.9 | (56.1-233.3) |
| Female | 1 | 1.3 | nc | (nc-nc) |  | Female | 2 | 7.3 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 4 | 1.1 | nc | (nc-nc) |  | Male | 61 | 59.0 | 103.5 | (79.1-132.9) |
| Female | 1 | 0.9 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 11 | 10.5 | 105.2 | (52.4-188.3) |  | Male | 1 | 4.9 | nc | (nc-nc) |
| Female | 6 | 5.7 | 105.7 | (38.6-230.0) |  | Female | 2 | 2.9 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 3 | 2.9 | nc | (nc-nc) |  | Male | 5 | 1.7 | 299.8 | (96.6-699.6) |
| Female | 0 | 0.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 9 | 8.1 | 111.2 | (50.7-211.1) |  | Male | 4 | 4.3 | nc | (nc-nc) |
| Female | 10 | 5.5 | 181.1 | (86.7-333.0) |  | Female | 18 | 11.5 | 156.3 | (92.6-247.1) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 8 | 6.6 | 120.9 | (52.1-238.2) |  |  |  |  |  |  |
| Female | 4 | 2.2 | nc | (nc-nc) |  | Female | 20 | 15.3 | 130.7 | (79.8-201.9) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 24 | 35.8 | 67.0 | (42.9-99.7) |  | Male | 254 | 253.3 | 100.3 | (88.3-113.4) |
| Female | 32 | 34.8 | 91.8 | (62.8-129.7) |  | Female | 296 | 244.4 | 121.1 | (107.7-135.7) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

344

# Weymouth

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 61 | 57.1 | 106.9 | (81.8-137.3) |  | Male | 41 | 37.0 | 110.7 | (79.4-150.1) |
| Female | 42 | 24.0 | 175.1 | (126.2-236.6) |  | Female | 47 | 32.6 | 144.1 | (105.9-191.7) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 11 | 11.3 | 97.1 | (48.4-173.7) |  | Male | 10 | 11.9 | 83.9 | (40.2-154.3) |
| Female | 10 | 10.3 | 97.4 | (46.6-179.2) |  | Female | 8 | 11.0 | 72.6 | (31.3-143.1) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 2.0 | nc | (nc-nc) |  | Male | 42 | 33.2 | 126.5 | (91.1-171.0) |
| Female | 287 | 265.7 | 108.0 | (95.9-121.3) |  | Female | 30 | 33.6 | 89.2 | (60.1-127.3) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 29 | 27.9 | 104.0 | (69.6-149.3) |
| Female | 4 | 8.7 | nc | (nc-nc) |  | Female | 20 | 14.1 | 141.5 | (86.4-218.5) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 69 | 62.6 | 110.3 | (85.8-139.6) |  |  |  |  |  |  |
| Female | 74 | 69.8 | 106.1 | (83.3-133.2) |  | Female | 22 | 22.8 | 96.4 | (60.4-146.0) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 19 | 14.9 | 127.3 | (76.6-198.8) |  | Male | 17 | 20.6 | 82.6 | (48.1-132.3) |
| Female | 5 | 4.7 | 106.8 | (34.4-249.2) |  | Female | 20 | 24.4 | 82.0 | (50.1-126.7) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 7 | 4.5 | 156.8 | (62.8-323.1) |  | Male | 172 | 181.6 | 94.7 | (81.1-110.0) |
| Female | 2 | 3.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 38 | 32.7 | 116.2 | (82.2-159.5) |  | Male | 16 | 13.9 | 114.7 | (65.5-186.3) |
| Female | 31 | 21.0 | 147.6 | (100.2-209.5) |  | Female | 7 | 9.4 | 74.1 | (29.7-152.7) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 14 | 8.8 | 159.7 | (87.2-268.0) |  | Male | 9 | 8.2 | 110.2 | (50.3-209.2) |
| Female | 4 | 3.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 19 | 23.5 | 81.0 | (48.8-126.5) |  | Male | 14 | 15.0 | 93.1 | (50.8-156.2) |
| Female | 14 | 19.1 | 73.5 | (40.1-123.3) |  | Female | 44 | 47.6 | 92.5 | (67.2-124.2) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 22 | 20.4 | 107.6 | (67.4-162.9) |  |  |  |  |  |  |
| Female | 9 | 7.9 | 114.0 | (52.0-216.5) |  | Female | 64 | 60.0 | 106.7 | (82.2-136.3) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 117 | 102.6 | 114.1 | (94.3-136.7) |  | Male | 799 | 749.6 | 106.6 | (99.3-114.2) |
| Female | 163 | 126.2 | 129.2 | (110.1-150.6) |  | Female | 971 | 891.5 | 108.9 | (102.2-116.0) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

345

# Whately

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 1 | 1.6 | nc | (nc-nc) |  | Male | 2 | 1.1 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 1 | 0.9 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 0 | 1.0 | nc | (nc-nc) |
| Female | 4 | 7.2 | nc | (nc-nc) |  | Female | 0 | 0.9 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 0.9 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 4 | 1.8 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 1.9 | nc | (nc-nc) |  | Female | 0 | 0.6 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 0.5 | nc | (nc-nc) |  | Male | 2 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 1 | 0.6 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 7 | 6.5 | 106.9 | (42.8-220.2) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 0 | 1.0 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 1 | 0.7 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 1 | 1.2 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.7 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 4 | 1.7 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 1 | 3.0 | nc | (nc-nc) |  | Male | 24 | 23.3 | 103.0 | (66.0-153.3) |
| Female | 2 | 3.1 | nc | (nc-nc) |  | Female | 13 | 23.6 | 55.0 | (29.3-94.1) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

346

# Whitman

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 24 | 12.5 | 192.0 | (123.0-285.6) |  | Male | 8 | 8.7 | 91.9 | (39.5-181.0) |
| Female | 8 | 4.5 | 176.7 | (76.1-348.2) |  | Female | 14 | 7.1 | 195.9 | (107.0-328.7) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 2.9 | nc | (nc-nc) |  | Male | 0 | 2.8 | nc | (nc-nc) |
| Female | 1 | 2.3 | nc | (nc-nc) |  | Female | 1 | 2.2 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 2 | 7.8 | nc | (nc-nc) |
| Female | 58 | 57.7 | 100.5 | (76.3-129.9) |  | Female | 5 | 6.8 | 73.7 | (23.8-172.0) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 7 | 7.0 | 100.3 | (40.2-206.7) |
| Female | 5 | 2.1 | 240.3 | (77.5-560.9) |  | Female | 6 | 2.9 | 205.3 | (75.0-446.8) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 16 | 14.5 | 110.2 | (62.9-178.9) |  |  |  |  |  |  |
| Female | 14 | 13.6 | 102.6 | (56.0-172.1) |  | Female | 3 | 4.9 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 6 | 3.5 | 169.7 | (62.0-369.5) |  | Male | 2 | 4.7 | nc | (nc-nc) |
| Female | 1 | 0.9 | nc | (nc-nc) |  | Female | 7 | 4.6 | 152.7 | (61.2-314.7) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 1.2 | nc | (nc-nc) |  | Male | 45 | 45.0 | 100.0 | (72.9-133.8) |
| Female | 0 | 1.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 17 | 8.1 | 210.2 | (122.4-336.5) |  | Male | 4 | 3.2 | nc | (nc-nc) |
| Female | 4 | 4.4 | nc | (nc-nc) |  | Female | 1 | 1.8 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 3 | 2.1 | nc | (nc-nc) |  | Male | 1 | 2.3 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 9 | 5.5 | 162.7 | (74.3-308.9) |  | Male | 2 | 4.0 | nc | (nc-nc) |
| Female | 3 | 4.0 | nc | (nc-nc) |  | Female | 9 | 11.7 | 76.7 | (35.0-145.6) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 4.9 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 1.6 | nc | (nc-nc) |  | Female | 7 | 13.0 | 53.9 | (21.6-111.1) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 32 | 23.1 | 138.3 | (94.6-195.3) |  | Male | 193 | 177.8 | 108.6 | (93.8-125.0) |
| Female | 43 | 24.6 | 174.6 | (126.3-235.2) |  | Female | 205 | 186.5 | 109.9 | (95.4-126.0) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

347

# Wilbraham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 18 | 21.3 | 84.6 | (50.1-133.7) |  | Male | 16 | 12.7 | 125.9 | (71.9-204.5) |
| Female | 10 | 7.0 | 142.2 | (68.1-261.5) |  | Female | 9 | 8.9 | 101.1 | (46.2-192.0) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 3 | 3.5 | nc | (nc-nc) |  | Male | 4 | 4.2 | nc | (nc-nc) |
| Female | 7 | 2.8 | 247.5 | (99.2-510.0) |  | Female | 2 | 3.2 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.7 | nc | (nc-nc) |  | Male | 9 | 11.5 | 78.4 | (35.8-148.8) |
| Female | 80 | 74.0 | 108.1 | (85.7-134.6) |  | Female | 11 | 9.5 | 115.4 | (57.5-206.5) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 8 | 9.3 | 85.6 | (36.9-168.7) |
| Female | 1 | 2.2 | nc | (nc-nc) |  | Female | 2 | 4.0 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 21 | 22.1 | 95.0 | (58.8-145.3) |  |  |  |  |  |  |
| Female | 15 | 20.7 | 72.4 | (40.5-119.5) |  | Female | 8 | 6.4 | 125.1 | (53.9-246.4) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 5.3 | nc | (nc-nc) |  | Male | 3 | 7.5 | nc | (nc-nc) |
| Female | 4 | 1.4 | nc | (nc-nc) |  | Female | 10 | 7.3 | 136.4 | (65.3-250.8) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 1.2 | nc | (nc-nc) |  | Male | 45 | 65.1 | 69.2 | (50.4-92.5) |
| Female | 1 | 0.9 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 10 | 11.0 | 91.2 | (43.6-167.7) |  | Male | 5 | 5.0 | 100.2 | (32.3-233.9) |
| Female | 4 | 5.9 | nc | (nc-nc) |  | Female | 3 | 2.8 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 3.0 | nc | (nc-nc) |  | Male | 1 | 1.8 | nc | (nc-nc) |
| Female | 1 | 0.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 3 | 8.1 | nc | (nc-nc) |  | Male | 4 | 4.5 | nc | (nc-nc) |
| Female | 7 | 5.5 | 128.0 | (51.3-263.8) |  | Female | 10 | 11.8 | 84.8 | (40.6-156.0) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 7 | 6.9 | 100.8 | (40.4-207.7) |  |  |  |  |  |  |
| Female | 2 | 2.2 | nc | (nc-nc) |  | Female | 12 | 16.5 | 72.8 | (37.5-127.1) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 25 | 37.2 | 67.1 | (43.4-99.1) |  | Male | 207 | 263.2 | 78.7 | (68.3-90.1) |
| Female | 24 | 35.7 | 67.2 | (43.0-100.0) |  | Female | 241 | 250.8 | 96.1 | (84.3-109.0) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

348

# Williamsburg

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 1 | 3.3 | nc | (nc-nc) |  | Male | 1 | 2.1 | nc | (nc-nc) |
| Female | 0 | 1.2 | nc | (nc-nc) |  | Female | 0 | 1.6 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  | Male | 0 | 0.7 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 1 | 1.9 | nc | (nc-nc) |
| Female | 18 | 13.6 | 132.7 | (78.6-209.8) |  | Female | 1 | 1.7 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 1 | 1.7 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 0 | 0.7 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 3 | 3.6 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 4 | 3.5 | nc | (nc-nc) |  | Female | 4 | 1.2 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 0.9 | nc | (nc-nc) |  | Male | 1 | 1.2 | nc | (nc-nc) |
| Female | 1 | 0.2 | nc | (nc-nc) |  | Female | 0 | 1.2 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 6 | 11.6 | 51.6 | (18.8-112.4) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 4 | 1.9 | nc | (nc-nc) |  | Male | 0 | 0.8 | nc | (nc-nc) |
| Female | 2 | 1.1 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 0.5 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 1 | 1.3 | nc | (nc-nc) |  | Male | 0 | 0.8 | nc | (nc-nc) |
| Female | 1 | 0.9 | nc | (nc-nc) |  | Female | 1 | 2.3 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 1.3 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 2 | 3.2 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 5 | 6.1 | 82.4 | (26.5-192.3) |  | Male | 30 | 44.2 | 67.8 | (45.7-96.8) |
| Female | 4 | 6.2 | nc | (nc-nc) |  | Female | 43 | 44.8 | 96.0 | (69.5-129.4) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

349

# Williamstown

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 10 | 10.6 | 94.7 | (45.3-174.2) |  | Male | 4 | 5.8 | nc | (nc-nc) |
| Female | 4 | 3.9 | nc | (nc-nc) |  | Female | 3 | 4.4 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 1.6 | nc | (nc-nc) |  | Male | 2 | 1.9 | nc | (nc-nc) |
| Female | 2 | 1.5 | nc | (nc-nc) |  | Female | 1 | 1.7 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 8 | 5.3 | 150.8 | (64.9-297.1) |
| Female | 25 | 33.8 | 74.0 | (47.9-109.3) |  | Female | 4 | 5.1 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 2 | 3.9 | nc | (nc-nc) |
| Female | 0 | 0.9 | nc | (nc-nc) |  | Female | 1 | 2.1 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 7 | 10.2 | 68.7 | (27.5-141.6) |  |  |  |  |  |  |
| Female | 8 | 11.1 | 71.9 | (31.0-141.7) |  | Female | 4 | 3.1 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 3 | 2.4 | nc | (nc-nc) |  | Male | 1 | 3.5 | nc | (nc-nc) |
| Female | 1 | 0.7 | nc | (nc-nc) |  | Female | 3 | 4.1 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  | Male | 25 | 27.6 | 90.5 | (58.5-133.5) |
| Female | 1 | 0.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 4 | 4.6 | nc | (nc-nc) |  | Male | 2 | 2.3 | nc | (nc-nc) |
| Female | 2 | 2.9 | nc | (nc-nc) |  | Female | 0 | 1.5 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 1.3 | nc | (nc-nc) |  | Male | 0 | 0.9 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 2 | 3.9 | nc | (nc-nc) |  | Male | 2 | 1.8 | nc | (nc-nc) |
| Female | 2 | 3.0 | nc | (nc-nc) |  | Female | 5 | 5.3 | 93.9 | (30.2-219.0) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 3.0 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 2 | 1.2 | nc | (nc-nc) |  | Female | 4 | 7.7 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 5 | 17.4 | 28.7 | (9.2-66.9) |  | Male | 84 | 119.5 | 70.3 | (56.1-87.1) |
| Female | 15 | 19.1 | 78.6 | (44.0-129.7) |  | Female | 94 | 126.1 | 74.6 | (60.2-91.2) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

350

# Wilmington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 21 | 22.7 | 92.3 | (57.1-141.1) |  | Male | 12 | 14.8 | 81.0 | (41.8-141.5) |
| Female | 9 | 8.4 | 107.6 | (49.1-204.2) |  | Female | 11 | 11.9 | 92.1 | (45.9-164.9) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 4 | 4.7 | nc | (nc-nc) |  | Male | 4 | 4.7 | nc | (nc-nc) |
| Female | 4 | 3.8 | nc | (nc-nc) |  | Female | 6 | 3.8 | 155.8 | (56.9-339.2) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.8 | nc | (nc-nc) |  | Male | 6 | 13.4 | 44.7 | (16.3-97.3) |
| Female | 127 | 96.4 | 131.7 | (109.8-156.7) |  | Female | 16 | 11.9 | 134.2 | (76.7-218.0) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 13 | 11.4 | 114.1 | (60.7-195.2) |
| Female | 3 | 3.3 | nc | (nc-nc) |  | Female | 3 | 5.1 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 22 | 25.5 | 86.2 | (54.0-130.5) |  |  |  |  |  |  |
| Female | 28 | 25.1 | 111.3 | (74.0-160.9) |  | Female | 5 | 8.3 | 60.5 | (19.5-141.2) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 4 | 5.9 | nc | (nc-nc) |  | Male | 6 | 8.3 | 72.7 | (26.5-158.2) |
| Female | 0 | 1.6 | nc | (nc-nc) |  | Female | 6 | 8.5 | 70.2 | (25.6-152.9) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 4 | 1.9 | nc | (nc-nc) |  | Male | 49 | 72.3 | 67.8 | (50.2-89.6) |
| Female | 1 | 1.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 21 | 13.2 | 159.0 | (98.4-243.1) |  | Male | 4 | 5.6 | nc | (nc-nc) |
| Female | 7 | 7.5 | 92.9 | (37.2-191.3) |  | Female | 5 | 3.4 | 146.3 | (47.1-341.4) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 3 | 3.4 | nc | (nc-nc) |  | Male | 2 | 3.3 | nc | (nc-nc) |
| Female | 0 | 1.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 14 | 9.6 | 145.1 | (79.3-243.5) |  | Male | 7 | 6.2 | 112.9 | (45.2-232.6) |
| Female | 5 | 6.9 | 72.1 | (23.2-168.1) |  | Female | 13 | 18.1 | 72.0 | (38.3-123.2) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 6 | 8.1 | 74.4 | (27.2-162.0) |  |  |  |  |  |  |
| Female | 2 | 2.8 | nc | (nc-nc) |  | Female | 21 | 21.2 | 99.0 | (61.2-151.3) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 46 | 39.7 | 115.9 | (84.9-154.6) |  | Male | 270 | 299.9 | 90.0 | (79.6-101.4) |
| Female | 43 | 43.7 | 98.4 | (71.2-132.6) |  | Female | 343 | 320.2 | 107.1 | (96.1-119.1) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

351

# Winchendon

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 11 | 11.7 | 93.7 | (46.7-167.6) |  | Male | 1 | 7.7 | nc | (nc-nc) |
| Female | 3 | 3.9 | nc | (nc-nc) |  | Female | 4 | 5.6 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 2.3 | nc | (nc-nc) |  | Male | 3 | 2.4 | nc | (nc-nc) |
| Female | 1 | 1.7 | nc | (nc-nc) |  | Female | 4 | 1.8 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 4 | 6.8 | nc | (nc-nc) |
| Female | 35 | 47.4 | 73.8 | (51.4-102.6) |  | Female | 4 | 5.7 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 7 | 5.9 | 119.0 | (47.7-245.2) |
| Female | 4 | 1.5 | nc | (nc-nc) |  | Female | 1 | 2.4 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 10 | 13.1 | 76.5 | (36.6-140.8) |  |  |  |  |  |  |
| Female | 16 | 11.6 | 138.3 | (79.0-224.6) |  | Female | 5 | 4.0 | 124.4 | (40.1-290.4) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 3.1 | nc | (nc-nc) |  | Male | 9 | 4.3 | 211.8 | (96.6-402.0) |
| Female | 1 | 0.8 | nc | (nc-nc) |  | Female | 5 | 3.9 | 127.3 | (41.0-297.0) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.9 | nc | (nc-nc) |  | Male | 26 | 37.2 | 69.8 | (45.6-102.3) |
| Female | 0 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 8 | 6.8 | 118.1 | (50.9-232.8) |  | Male | 2 | 2.9 | nc | (nc-nc) |
| Female | 5 | 3.7 | 136.5 | (44.0-318.6) |  | Female | 2 | 1.5 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 1.8 | nc | (nc-nc) |  | Male | 2 | 1.5 | nc | (nc-nc) |
| Female | 1 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 6 | 4.9 | 123.5 | (45.1-268.7) |  | Male | 2 | 3.1 | nc | (nc-nc) |
| Female | 1 | 3.1 | nc | (nc-nc) |  | Female | 7 | 8.5 | 82.4 | (33.0-169.8) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 4.3 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 1.3 | nc | (nc-nc) |  | Female | 9 | 10.6 | 84.9 | (38.7-161.1) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 14 | 21.1 | 66.5 | (36.3-111.6) |  | Male | 120 | 154.6 | 77.6 | (64.3-92.8) |
| Female | 19 | 21.5 | 88.2 | (53.1-137.8) |  | Female | 136 | 153.6 | 88.6 | (74.3-104.8) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

352

# Winchester

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 22 | 23.6 | 93.4 | (58.5-141.4) |  | Male | 16 | 15.0 | 106.5 | (60.8-172.9) |
| Female | 6 | 9.1 | 66.2 | (24.2-144.1) |  | Female | 13 | 12.1 | 107.8 | (57.3-184.3) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 4 | 4.6 | nc | (nc-nc) |  | Male | 5 | 4.9 | 102.0 | (32.9-238.1) |
| Female | 7 | 4.0 | 175.3 | (70.2-361.2) |  | Female | 3 | 4.1 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.8 | nc | (nc-nc) |  | Male | 17 | 13.5 | 125.6 | (73.1-201.1) |
| Female | 116 | 100.8 | 115.0 | (95.1-138.0) |  | Female | 15 | 12.6 | 119.3 | (66.7-196.8) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 5 | 11.2 | 44.6 | (14.4-104.1) |
| Female | 2 | 3.3 | nc | (nc-nc) |  | Female | 5 | 5.3 | 94.1 | (30.3-219.6) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 28 | 25.7 | 108.9 | (72.4-157.5) |  |  |  |  |  |  |
| Female | 27 | 27.0 | 99.8 | (65.8-145.3) |  | Female | 8 | 8.5 | 93.8 | (40.4-184.8) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 3 | 6.1 | nc | (nc-nc) |  | Male | 5 | 8.4 | 59.2 | (19.1-138.1) |
| Female | 0 | 1.8 | nc | (nc-nc) |  | Female | 10 | 9.4 | 106.6 | (51.0-196.1) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 1.6 | nc | (nc-nc) |  | Male | 70 | 72.7 | 96.3 | (75.1-121.7) |
| Female | 1 | 1.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 5 | 13.3 | 37.7 | (12.1-87.9) |  | Male | 4 | 5.7 | nc | (nc-nc) |
| Female | 12 | 7.9 | 151.8 | (78.4-265.2) |  | Female | 3 | 3.7 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 3.6 | nc | (nc-nc) |  | Male | 2 | 2.6 | nc | (nc-nc) |
| Female | 0 | 1.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 15 | 9.6 | 156.5 | (87.5-258.1) |  | Male | 5 | 5.9 | 84.4 | (27.2-196.9) |
| Female | 7 | 7.4 | 95.2 | (38.1-196.1) |  | Female | 24 | 17.7 | 136.0 | (87.1-202.3) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 6 | 8.1 | 73.8 | (26.9-160.6) |  |  |  |  |  |  |
| Female | 2 | 2.9 | nc | (nc-nc) |  | Female | 24 | 21.8 | 110.1 | (70.5-163.9) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 22 | 42.3 | 52.0 | (32.6-78.7) |  | Male | 266 | 303.8 | 87.6 | (77.4-98.8) |
| Female | 43 | 47.0 | 91.5 | (66.2-123.2) |  | Female | 353 | 336.4 | 104.9 | (94.3-116.5) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

353

# Windsor

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 0 | 1.3 | nc | (nc-nc) |  | Male | 0 | 0.9 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 0.2 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 1 | 0.8 | nc | (nc-nc) |
| Female | 4 | 4.2 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 0.7 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 5 | 1.5 | 334.4 | (107.8-780.4) |  |  |  |  |  |  |
| Female | 3 | 1.0 | nc | (nc-nc) |  | Female | 1 | 0.4 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 1 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 1 | 0.3 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 0 | 4.7 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 0 | 0.8 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 1 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 1 | 0.5 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 1 | 0.7 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 2 | 1.0 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 1 | 2.4 | nc | (nc-nc) |  | Male | 11 | 18.0 | 61.2 | (30.5-109.5) |
| Female | 4 | 1.8 | nc | (nc-nc) |  | Female | 20 | 13.4 | 149.6 | (91.3-231.0) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

354

# Winthrop

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 21 | 22.1 | 95.1 | (58.8-145.3) |  | Male | 28 | 14.2 | 197.6 | (131.3-285.6) |
| Female | 9 | 6.9 | 129.6 | (59.1-246.0) |  | Female | 19 | 10.0 | 189.6 | (114.1-296.0) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 4.2 | nc | (nc-nc) |  | Male | 5 | 4.6 | 108.0 | (34.8-252.1) |
| Female | 2 | 3.1 | nc | (nc-nc) |  | Female | 6 | 3.2 | 186.2 | (68.0-405.4) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.8 | nc | (nc-nc) |  | Male | 6 | 12.6 | 47.6 | (17.4-103.7) |
| Female | 83 | 81.5 | 101.9 | (81.1-126.3) |  | Female | 8 | 10.0 | 80.2 | (34.5-158.0) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 10 | 10.8 | 93.0 | (44.5-171.0) |
| Female | 3 | 2.7 | nc | (nc-nc) |  | Female | 2 | 4.2 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 25 | 23.5 | 106.3 | (68.8-157.0) |  |  |  |  |  |  |
| Female | 28 | 20.2 | 138.9 | (92.3-200.7) |  | Female | 6 | 7.0 | 86.1 | (31.4-187.4) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 7 | 5.9 | 118.4 | (47.4-243.9) |  | Male | 15 | 8.0 | 188.0 | (105.1-310.0) |
| Female | 1 | 1.4 | nc | (nc-nc) |  | Female | 5 | 7.0 | 71.8 | (23.1-167.5) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 1.6 | nc | (nc-nc) |  | Male | 69 | 74.5 | 92.6 | (72.1-117.2) |
| Female | 1 | 1.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 25 | 12.7 | 197.5 | (127.7-291.5) |  | Male | 5 | 5.4 | 93.2 | (30.0-217.6) |
| Female | 12 | 6.4 | 187.2 | (96.6-327.0) |  | Female | 3 | 2.7 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 4 | 3.5 | nc | (nc-nc) |  | Male | 2 | 2.7 | nc | (nc-nc) |
| Female | 0 | 0.9 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 5 | 8.8 | 56.7 | (18.3-132.2) |  | Male | 7 | 5.5 | 127.1 | (50.9-261.9) |
| Female | 6 | 5.6 | 106.6 | (38.9-232.1) |  | Female | 14 | 15.2 | 91.9 | (50.2-154.2) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 9 | 8.0 | 112.3 | (51.3-213.3) |  |  |  |  |  |  |
| Female | 1 | 2.3 | nc | (nc-nc) |  | Female | 19 | 18.4 | 103.1 | (62.1-161.1) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 53 | 40.9 | 129.7 | (97.2-169.7) |  | Male | 325 | 292.5 | 111.1 | (99.4-123.9) |
| Female | 43 | 37.9 | 113.5 | (82.2-152.9) |  | Female | 292 | 268.7 | 108.7 | (96.6-121.9) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

355

# Woburn

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 52 | 41.0 | 126.8 | (94.7-166.3) |  | Male | 29 | 26.4 | 109.9 | (73.6-157.9) |
| Female | 21 | 16.3 | 129.0 | (79.8-197.2) |  | Female | 17 | 22.0 | 77.3 | (45.0-123.8) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 5 | 8.1 | 61.6 | (19.9-143.8) |  | Male | 10 | 8.2 | 121.2 | (58.0-223.0) |
| Female | 11 | 6.9 | 160.5 | (80.0-287.2) |  | Female | 8 | 7.3 | 109.3 | (47.0-215.3) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 1.4 | nc | (nc-nc) |  | Male | 34 | 23.6 | 144.1 | (99.8-201.4) |
| Female | 214 | 171.8 | 124.6 | (108.5-142.4) |  | Female | 30 | 22.5 | 133.2 | (89.9-190.2) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 17 | 19.3 | 88.2 | (51.4-141.3) |
| Female | 8 | 5.8 | 138.6 | (59.7-273.0) |  | Female | 6 | 9.3 | 64.2 | (23.5-139.8) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 60 | 44.5 | 134.9 | (102.9-173.6) |  |  |  |  |  |  |
| Female | 53 | 48.0 | 110.4 | (82.7-144.3) |  | Female | 15 | 15.0 | 100.0 | (55.9-165.0) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 12 | 10.4 | 115.9 | (59.8-202.5) |  | Male | 12 | 14.6 | 82.0 | (42.3-143.3) |
| Female | 1 | 3.1 | nc | (nc-nc) |  | Female | 19 | 16.7 | 114.1 | (68.6-178.1) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 3 | 3.4 | nc | (nc-nc) |  | Male | 120 | 124.7 | 96.2 | (79.8-115.1) |
| Female | 1 | 2.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 24 | 22.7 | 105.7 | (67.7-157.3) |  | Male | 8 | 9.9 | 80.7 | (34.7-158.9) |
| Female | 16 | 13.8 | 115.9 | (66.2-188.2) |  | Female | 6 | 6.6 | 91.4 | (33.4-199.0) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 4 | 6.0 | nc | (nc-nc) |  | Male | 6 | 6.5 | 91.7 | (33.5-199.6) |
| Female | 6 | 1.9 | 311.3 | (113.7-677.6) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 21 | 16.9 | 124.5 | (77.0-190.3) |  | Male | 14 | 10.7 | 130.6 | (71.3-219.1) |
| Female | 11 | 13.1 | 83.7 | (41.7-149.8) |  | Female | 37 | 31.7 | 116.8 | (82.2-161.0) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 16 | 14.1 | 113.7 | (65.0-184.7) |  |  |  |  |  |  |
| Female | 3 | 5.2 | nc | (nc-nc) |  | Female | 35 | 37.8 | 92.5 | (64.4-128.7) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 98 | 72.2 | 135.7 | (110.2-165.4) |  | Male | 607 | 527.9 | 115.0 | (106.0-124.5) |
| Female | 82 | 83.0 | 98.7 | (78.5-122.6) |  | Female | 664 | 590.1 | 112.5 | (104.1-121.4) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

356

# Worcester

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 169 | 150.9 | 112.0 | (95.8-130.2) |  | Male | 72 | 99.2 | 72.6 | (56.8-91.4) |
| Female | 60 | 62.0 | 96.8 | (73.9-124.6) |  | Female | 61 | 88.7 | 68.7 | (52.6-88.3) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 32 | 33.0 | 97.0 | (66.3-136.9) |  | Male | 24 | 31.0 | 77.4 | (49.6-115.2) |
| Female | 23 | 29.2 | 78.7 | (49.9-118.2) |  | Female | 27 | 28.1 | 96.1 | (63.3-139.8) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 2 | 5.2 | nc | (nc-nc) |  | Male | 105 | 89.8 | 116.9 | (95.6-141.5) |
| Female | 617 | 676.9 | 91.1 | (84.1-98.6) |  | Female | 72 | 87.4 | 82.4 | (64.5-103.8) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 72 | 74.0 | 97.3 | (76.1-122.5) |
| Female | 30 | 24.2 | 124.2 | (83.8-177.3) |  | Female | 37 | 36.7 | 100.9 | (71.0-139.1) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 156 | 167.6 | 93.1 | (79.0-108.9) |  |  |  |  |  |  |
| Female | 177 | 185.0 | 95.7 | (82.1-110.9) |  | Female | 47 | 59.4 | 79.1 | (58.1-105.2) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 53 | 38.9 | 136.3 | (102.1-178.3) |  | Male | 52 | 54.3 | 95.8 | (71.5-125.6) |
| Female | 18 | 11.9 | 151.3 | (89.6-239.1) |  | Female | 63 | 63.5 | 99.2 | (76.2-126.9) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 14 | 15.1 | 92.9 | (50.8-155.9) |  | Male | 476 | 470.6 | 101.2 | (92.3-110.7) |
| Female | 18 | 13.4 | 134.5 | (79.6-212.5) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 93 | 86.4 | 107.6 | (86.9-131.8) |  | Male | 35 | 36.9 | 94.9 | (66.1-132.0) |
| Female | 64 | 54.3 | 117.9 | (90.8-150.5) |  | Female | 22 | 25.1 | 87.6 | (54.9-132.6) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 19 | 22.6 | 84.2 | (50.7-131.6) |  | Male | 23 | 29.0 | 79.3 | (50.2-119.0) |
| Female | 12 | 7.5 | 159.8 | (82.5-279.2) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 74 | 65.5 | 113.0 | (88.7-141.9) |  | Male | 44 | 42.6 | 103.4 | (75.1-138.8) |
| Female | 52 | 53.1 | 97.8 | (73.1-128.3) |  | Female | 131 | 137.9 | 95.0 | (79.4-112.7) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 82 | 53.9 | 152.2 | (121.1-188.9) |  |  |  |  |  |  |
| Female | 26 | 20.1 | 129.1 | (84.3-189.2) |  | Female | 167 | 148.2 | 112.7 | (96.2-131.1) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 325 | 264.2 | 123.0 | (110.0-137.2) |  | Male | 2080 | 1994.9 | 104.3 | (99.8-108.8) |
| Female | 350 | 318.6 | 109.8 | (98.6-122.0) |  | Female | 2274 | 2324.2 | 97.8 | (93.9-101.9) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

357

# Worthington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 2 | 2.0 | nc | (nc-nc) |  | Male | 0 | 1.2 | nc | (nc-nc) |
| Female | 1 | 0.5 | nc | (nc-nc) |  | Female | 1 | 0.8 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.1 | nc | (nc-nc) |  | Male | 3 | 1.1 | nc | (nc-nc) |
| Female | 5 | 6.3 | 78.8 | (25.4-183.8) |  | Female | 1 | 0.7 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 0.9 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 2 | 2.0 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 3 | 1.5 | nc | (nc-nc) |  | Female | 0 | 0.6 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 0.5 | nc | (nc-nc) |  | Male | 0 | 0.7 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 1 | 0.5 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 3 | 6.5 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 1 | 1.0 | nc | (nc-nc) |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 1 | 0.5 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 2 | 0.7 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 0 | 1.1 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 0.7 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 5 | 1.6 | 318.7 | (102.7-743.6) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 7 | 3.5 | 200.4 | (80.3-413.0) |  | Male | 26 | 25.0 | 103.8 | (67.8-152.1) |
| Female | 0 | 2.8 | nc | (nc-nc) |  | Female | 21 | 20.4 | 102.7 | (63.6-157.1) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

358

# Wrentham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 10 | 9.7 | 103.5 | (49.6-190.4) |  | Male | 9 | 6.8 | 132.7 | (60.6-252.0) |
| Female | 4 | 4.4 | nc | (nc-nc) |  | Female | 10 | 6.2 | 160.1 | (76.6-294.4) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 2.2 | nc | (nc-nc) |  | Male | 0 | 2.1 | nc | (nc-nc) |
| Female | 3 | 2.0 | nc | (nc-nc) |  | Female | 1 | 2.0 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 14 | 6.1 | 229.1 | (125.2-384.5) |
| Female | 64 | 51.4 | 124.5 | (95.9-159.0) |  | Female | 5 | 6.3 | 78.9 | (25.4-184.1) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 3 | 5.5 | nc | (nc-nc) |
| Female | 2 | 1.7 | nc | (nc-nc) |  | Female | 4 | 2.7 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 19 | 11.8 | 160.6 | (96.6-250.8) |  |  |  |  |  |  |
| Female | 12 | 13.6 | 88.2 | (45.5-154.1) |  | Female | 6 | 4.4 | 136.6 | (49.9-297.4) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 5 | 2.7 | 186.8 | (60.2-435.9) |  | Male | 5 | 3.7 | 135.4 | (43.6-316.0) |
| Female | 0 | 0.8 | nc | (nc-nc) |  | Female | 5 | 4.5 | 111.8 | (36.0-260.9) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.9 | nc | (nc-nc) |  | Male | 56 | 33.0 | 169.8 | (128.3-220.5) |
| Female | 1 | 0.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 6 | 6.2 | 96.3 | (35.2-209.5) |  | Male | 3 | 2.5 | nc | (nc-nc) |
| Female | 4 | 4.0 | nc | (nc-nc) |  | Female | 1 | 1.8 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 1.6 | nc | (nc-nc) |  | Male | 2 | 1.5 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 4 | 4.2 | nc | (nc-nc) |  | Male | 4 | 3.0 | nc | (nc-nc) |
| Female | 1 | 3.6 | nc | (nc-nc) |  | Female | 8 | 9.2 | 87.1 | (37.5-171.6) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 4 | 4.0 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 3 | 1.5 | nc | (nc-nc) |  | Female | 6 | 11.2 | 53.4 | (19.5-116.2) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 19 | 17.4 | 109.0 | (65.6-170.2) |  | Male | 179 | 136.0 | 131.6 | (113.0-152.3) |
| Female | 15 | 22.8 | 65.7 | (36.7-108.3) |  | Female | 165 | 169.3 | 97.4 | (83.1-113.5) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

359

# Yarmouth

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 54 | 46.2 | 116.9 | (87.8-152.6) |  | Male | 42 | 25.3 | 166.0 | (119.6-224.4) |
| Female | 21 | 17.2 | 122.1 | (75.6-186.7) |  | Female | 43 | 18.6 | 230.8 | (167.0-310.8) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 8 | 6.4 | 125.8 | (54.2-247.9) |  | Male | 7 | 8.4 | 83.6 | (33.5-172.3) |
| Female | 8 | 5.9 | 136.7 | (58.9-269.4) |  | Female | 8 | 7.4 | 108.4 | (46.7-213.6) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 1.4 | nc | (nc-nc) |  | Male | 25 | 22.8 | 109.9 | (71.1-162.2) |
| Female | 179 | 154.9 | 115.5 | (99.2-133.8) |  | Female | 24 | 21.8 | 109.9 | (70.4-163.5) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 19 | 16.1 | 118.1 | (71.1-184.5) |
| Female | 1 | 4.2 | nc | (nc-nc) |  | Female | 14 | 8.8 | 159.6 | (87.2-267.7) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 40 | 44.2 | 90.5 | (64.6-123.2) |  |  |  |  |  |  |
| Female | 37 | 47.1 | 78.5 | (55.3-108.2) |  | Female | 9 | 13.6 | 66.4 | (30.3-126.0) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 17 | 10.2 | 167.0 | (97.3-267.5) |  | Male | 18 | 15.1 | 119.4 | (70.7-188.8) |
| Female | 6 | 3.3 | 184.1 | (67.2-400.8) |  | Female | 19 | 17.3 | 109.5 | (65.9-171.1) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 4 | 2.0 | nc | (nc-nc) |  | Male | 140 | 110.7 | 126.4 | (106.4-149.2) |
| Female | 3 | 1.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 15 | 19.6 | 76.5 | (42.8-126.2) |  | Male | 6 | 10.3 | 58.4 | (21.3-127.0) |
| Female | 12 | 13.2 | 91.2 | (47.1-159.3) |  | Female | 7 | 6.4 | 108.5 | (43.5-223.6) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 4 | 5.7 | nc | (nc-nc) |  | Male | 2 | 2.9 | nc | (nc-nc) |
| Female | 1 | 1.9 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 35 | 16.3 | 214.5 | (149.4-298.3) |  | Male | 9 | 7.3 | 123.0 | (56.1-233.4) |
| Female | 21 | 12.3 | 170.7 | (105.6-260.9) |  | Female | 11 | 21.7 | 50.7 | (25.3-90.7) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 19 | 12.6 | 150.2 | (90.4-234.6) |  |  |  |  |  |  |
| Female | 9 | 5.2 | 174.8 | (79.7-331.8) |  | Female | 29 | 34.2 | 84.7 | (56.7-121.7) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 78 | 76.5 | 101.9 | (80.5-127.2) |  | Male | 581 | 505.6 | 114.9 | (105.8-124.6) |
| Female | 99 | 88.6 | 111.8 | (90.9-136.1) |  | Female | 611 | 553.9 | 110.3 | (101.7-119.4) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

360